
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High‐Risk Diffuse Large B Cell Lymphoma - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E481DE8AEECAE30581DE004545BB3A.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374179/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Hematological Oncology">
<meta name="citation_title" content="Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High‐Risk Diffuse Large B Cell Lymphoma">
<meta name="citation_author" content="Sara Ovejero">
<meta name="citation_author_institution" content="Department of Biological Hematology, CHU Montpellier, Montpellier, France">
<meta name="citation_author_institution" content="IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France">
<meta name="citation_author" content="Julie Devin">
<meta name="citation_author_institution" content="Department of Biological Hematology, CHU Montpellier, Montpellier, France">
<meta name="citation_author_institution" content="IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France">
<meta name="citation_author" content="Laura Alibert">
<meta name="citation_author_institution" content="IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France">
<meta name="citation_author" content="Camille Soun">
<meta name="citation_author_institution" content="Aix Marseille University, CNRS, INSERM, Centre d&#x27;Immunologie de Marseille‐Luminy, Marseille, France">
<meta name="citation_author" content="Yea‐Lih Lin">
<meta name="citation_author_institution" content="IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France">
<meta name="citation_author" content="Laure Dutrieux">
<meta name="citation_author_institution" content="Department of Biological Hematology, CHU Montpellier, Montpellier, France">
<meta name="citation_author_institution" content="IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France">
<meta name="citation_author" content="Matthieu Abouladze">
<meta name="citation_author_institution" content="Department of Biological Hematology, CHU Montpellier, Montpellier, France">
<meta name="citation_author" content="Elvira Garcia de Paco">
<meta name="citation_author_institution" content="Department of Biological Hematology, CHU Montpellier, Montpellier, France">
<meta name="citation_author" content="Ouissem Karmous Gadacha">
<meta name="citation_author_institution" content="Department of Biological Hematology, CHU Montpellier, Montpellier, France">
<meta name="citation_author" content="Angelos Constantinou">
<meta name="citation_author_institution" content="IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France">
<meta name="citation_author" content="Guillaume Cartron">
<meta name="citation_author_institution" content="Englander Institute for Precisiom Medicine, Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York, USA">
<meta name="citation_author_institution" content="Department of Clinical Hematology, CHU Montpellier, Montpellier, France">
<meta name="citation_author_institution" content="University of Montpellier, University of Medicine, Montpellier, France">
<meta name="citation_author" content="Charles Herbaux">
<meta name="citation_author_institution" content="IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France">
<meta name="citation_author_institution" content="Department of Clinical Hematology, CHU Montpellier, Montpellier, France">
<meta name="citation_author_institution" content="University of Montpellier, University of Medicine, Montpellier, France">
<meta name="citation_author" content="Olivier Elemento">
<meta name="citation_author_institution" content="Englander Institute for Precisiom Medicine, Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York, USA">
<meta name="citation_author" content="Philippe Pasero">
<meta name="citation_author_institution" content="IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France">
<meta name="citation_author" content="Sandrine Roulland">
<meta name="citation_author_institution" content="Aix Marseille University, CNRS, INSERM, Centre d&#x27;Immunologie de Marseille‐Luminy, Marseille, France">
<meta name="citation_author" content="Jérôme Moreaux">
<meta name="citation_author_institution" content="Department of Biological Hematology, CHU Montpellier, Montpellier, France">
<meta name="citation_author_institution" content="IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France">
<meta name="citation_author_institution" content="University of Montpellier, University of Medicine, Montpellier, France">
<meta name="citation_author_institution" content="Institut Universitaire de France (IUF), Paris, France">
<meta name="citation_author" content="Caroline Bret">
<meta name="citation_author_institution" content="Department of Biological Hematology, CHU Montpellier, Montpellier, France">
<meta name="citation_author_institution" content="IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France">
<meta name="citation_author_institution" content="University of Montpellier, University of Medicine, Montpellier, France">
<meta name="citation_publication_date" content="2025 Aug 23">
<meta name="citation_volume" content="43">
<meta name="citation_issue" content="5">
<meta name="citation_firstpage" content="e70131">
<meta name="citation_doi" content="10.1002/hon.70131">
<meta name="citation_pmid" content="40847617">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374179/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374179/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374179/pdf/HON-43-e70131.pdf">
<meta name="description" content="Diffuse large B‐cell lymphoma (DLBCL) is the most common hematological malignancy. More than half of DLBCL patients achieve long‐term remission after treatment, but a third relapse after conventional Rituximab (R)‐based chemotherapy regimens, such ...">
<meta name="og:title" content="Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High‐Risk Diffuse Large B Cell Lymphoma">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Diffuse large B‐cell lymphoma (DLBCL) is the most common hematological malignancy. More than half of DLBCL patients achieve long‐term remission after treatment, but a third relapse after conventional Rituximab (R)‐based chemotherapy regimens, such ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374179/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12374179">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/hon.70131"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/HON-43-e70131.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374179%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12374179/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12374179/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374179/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1002/hon.70131" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Hematol Oncol</button></div>. 2025 Aug 23;43(5):e70131. doi: <a href="https://doi.org/10.1002/hon.70131" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/hon.70131</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Hematol%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hematol%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Hematol%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Hematol%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High‐Risk Diffuse Large B Cell Lymphoma</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ovejero%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Sara Ovejero</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Sara Ovejero</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Biological Hematology, CHU Montpellier, Montpellier, France</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ovejero%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sara Ovejero</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Devin%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Julie Devin</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Julie Devin</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Biological Hematology, CHU Montpellier, Montpellier, France</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Devin%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Julie Devin</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alibert%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Laura Alibert</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Laura Alibert</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alibert%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Laura Alibert</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Soun%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Camille Soun</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Camille Soun</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille‐Luminy, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Soun%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Camille Soun</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lin%20YL%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Yea‐Lih Lin</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Yea‐Lih Lin</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lin%20YL%22%5BAuthor%5D" class="usa-link"><span class="name western">Yea‐Lih Lin</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dutrieux%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Laure Dutrieux</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Laure Dutrieux</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Biological Hematology, CHU Montpellier, Montpellier, France</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dutrieux%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Laure Dutrieux</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abouladze%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Matthieu Abouladze</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Matthieu Abouladze</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Biological Hematology, CHU Montpellier, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abouladze%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Matthieu Abouladze</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Garcia%20de%20Paco%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Elvira Garcia de Paco</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Elvira Garcia de Paco</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Biological Hematology, CHU Montpellier, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Garcia%20de%20Paco%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Elvira Garcia de Paco</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Karmous%20Gadacha%20O%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Ouissem Karmous Gadacha</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Ouissem Karmous Gadacha</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Biological Hematology, CHU Montpellier, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Karmous%20Gadacha%20O%22%5BAuthor%5D" class="usa-link"><span class="name western">Ouissem Karmous Gadacha</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Constantinou%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Angelos Constantinou</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Angelos Constantinou</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Constantinou%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Angelos Constantinou</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cartron%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Guillaume Cartron</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Guillaume Cartron</span></h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Englander Institute for Precisiom Medicine, Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York, USA</div>
<div class="p">
<sup>
<sup>5</sup>
</sup>Department of Clinical Hematology, CHU Montpellier, Montpellier, France</div>
<div class="p">
<sup>
<sup>6</sup>
</sup>University of Montpellier, University of Medicine, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cartron%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Guillaume Cartron</span></a>
</div>
</div>
<sup>4,</sup><sup>5,</sup><sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Herbaux%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Charles Herbaux</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Charles Herbaux</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France</div>
<div class="p">
<sup>
<sup>5</sup>
</sup>Department of Clinical Hematology, CHU Montpellier, Montpellier, France</div>
<div class="p">
<sup>
<sup>6</sup>
</sup>University of Montpellier, University of Medicine, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Herbaux%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Charles Herbaux</span></a>
</div>
</div>
<sup>2,</sup><sup>5,</sup><sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elemento%20O%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Olivier Elemento</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Olivier Elemento</span></h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Englander Institute for Precisiom Medicine, Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elemento%20O%22%5BAuthor%5D" class="usa-link"><span class="name western">Olivier Elemento</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pasero%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Philippe Pasero</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Philippe Pasero</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pasero%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Philippe Pasero</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Roulland%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Sandrine Roulland</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Sandrine Roulland</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille‐Luminy, Marseille, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Roulland%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sandrine Roulland</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Moreaux%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Jérôme Moreaux</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Jérôme Moreaux</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Biological Hematology, CHU Montpellier, Montpellier, France</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France</div>
<div class="p">
<sup>
<sup>6</sup>
</sup>University of Montpellier, University of Medicine, Montpellier, France</div>
<div class="p">
<sup>
<sup>7</sup>
</sup>Institut Universitaire de France (IUF), Paris, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Moreaux%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jérôme Moreaux</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>6,</sup><sup>7,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bret%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Caroline Bret</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">Caroline Bret</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Biological Hematology, CHU Montpellier, Montpellier, France</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France</div>
<div class="p">
<sup>
<sup>6</sup>
</sup>University of Montpellier, University of Medicine, Montpellier, France</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bret%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Caroline Bret</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>6,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="hon70131-aff-0001">
<sup>
<sup>1</sup>
</sup>Department of Biological Hematology, CHU Montpellier, Montpellier, France</div>
<div id="hon70131-aff-0002">
<sup>
<sup>2</sup>
</sup>IGH, Univ Montpellier, CNRS, CHU Montpellier, Montpellier, France</div>
<div id="hon70131-aff-0003">
<sup>
<sup>3</sup>
</sup>Aix Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille‐Luminy, Marseille, France</div>
<div id="hon70131-aff-0004">
<sup>
<sup>4</sup>
</sup>Englander Institute for Precisiom Medicine, Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York, USA</div>
<div id="hon70131-aff-0005">
<sup>
<sup>5</sup>
</sup>Department of Clinical Hematology, CHU Montpellier, Montpellier, France</div>
<div id="hon70131-aff-0006">
<sup>
<sup>6</sup>
</sup>University of Montpellier, University of Medicine, Montpellier, France</div>
<div id="hon70131-aff-0007">
<sup>
<sup>7</sup>
</sup>Institut Universitaire de France (IUF), Paris, France</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong> Jérôme Moreaux, 
(<span>jerome.moreaux@igh.cnrs.fr</span>) and, 
Caroline Bret, 
(<span>caroline.bret@igh.cnrs.fr</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Aug 7; Received 2025 Apr 14; Accepted 2025 Aug 11; Issue date 2025 Sep.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Hematological Oncology</em> published by John Wiley &amp; Sons Ltd.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12374179  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40847617/" class="usa-link">40847617</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<p>Diffuse large B‐cell lymphoma (DLBCL) is the most common hematological malignancy. More than half of DLBCL patients achieve long‐term remission after treatment, but a third relapse after conventional Rituximab (R)‐based chemotherapy regimens, such as CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone). Cancer cells are exposed to chronic replication stress, which impedes the duplication of their genome. Functional DNA repair pathways are therefore important for the survival of cancer cells. This dependence can be exploited therapeutically to hamper repair of the intrinsic DNA damage occurring during replication or to exacerbate DNA damage induced by chemotherapy. Using CRISPR‐Cas9 screening, we identified <em>CHEK1, WEE1, ATR</em> and <em>RAD51</em> DNA repair factors as essential genes in DLBCL cells. According to these results, we investigated the effect of small molecules targeting DNA replication stress and DNA repair mechanisms, alone or in combination with the R‐CHOP genotoxic agents, cyclophosphamide and doxorubicin. Applying a standard threshold of 2 SDs below the IC50 of the genotoxic agent alone, a total of 3 synthetic lethal combinations have been identified including cyclophosphamide with CHK1/2 inhibitor, cyclophosphamide and ATR inhibitor and doxorubicin with DNAPK inhibitor. Co‐treatment with these molecules led to cell death, DNA damage induction and cell cycle arrest in DLBCL cells more efficiently than genotoxic agents alone. These data have been validated using primary DLBCL cells from patients. Our results open new perspectives for therapeutic approaches exploiting the synthetic lethality of genotoxic agents with DNA repair inhibitors to improve the therapeutic outcome of patients with DLBCL.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> biomarker, CRISPR‐Cas9, DLBCL, DNA damage, DNA repair, genotoxic stress, inhibitors</p></section></section><section id="hon70131-sec-0010"><h2 class="pmc_sec_title">1. Background</h2>
<p>Diffuse large B‐cell lymphoma (DLBCL) is the most common type of non‐Hodgkin lymphoma (NHL) worlwide. DLBCL is primarily treated with R‐CHOP, a regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone [<a href="#hon70131-bib-0001" class="usa-link" aria-describedby="hon70131-bib-0001">1</a>]. However, a substantial fraction of patients with relapsed/refractory disease continue to die from this disease of the associated complications. Based on the cell of origin, two main gene‐expression based‐subgroups have been identified including the germinal center B‐cell group (GCB) and the activated B‐cell group (ABC). GCB and ABC account for 50% and 30% of DLBCL cases, respectively, and the remaining 20% of patients present rare or unclassifiable types of large B‐cell lymphomas [<a href="#hon70131-bib-0002" class="usa-link" aria-describedby="hon70131-bib-0002">2</a>, <a href="#hon70131-bib-0003" class="usa-link" aria-describedby="hon70131-bib-0003">3</a>]. GCB and ABC are heterogeneous diseases, and are associated with different prognosis and responses to treatment, with ABC being more aggressive and having a poorer prognosis [<a href="#hon70131-bib-0004" class="usa-link" aria-describedby="hon70131-bib-0004">4</a>]. More recently, large‐scale genomic studies have identified genetic subtypes of DLBCL based on shared genomic abnormalities, a classification i.e. not necessarily overlapping with the COO subgroups [<a href="#hon70131-bib-0005" class="usa-link" aria-describedby="hon70131-bib-0005">5</a>, <a href="#hon70131-bib-0006" class="usa-link" aria-describedby="hon70131-bib-0006">6</a>, <a href="#hon70131-bib-0007" class="usa-link" aria-describedby="hon70131-bib-0007">7</a>]. Finally, a transcriptomic analysis of the microenvironment based on deconvolution of large DLBCL cohorts revealed four distinct microenvironment compositions associated with distinct clinical behavior and biological subtypes of DLBCL [<a href="#hon70131-bib-0008" class="usa-link" aria-describedby="hon70131-bib-0008">8</a>].</p>
<p>Currently, R‐CHOP achieves cure in approximately 60% of DLBCL patients [<a href="#hon70131-bib-0001" class="usa-link" aria-describedby="hon70131-bib-0001">1</a>]. Unfortunately, 40% of DLBCL patients have primary refractory disease or relapse shortly after remission (i.e., therapy‐resistant) and continue to die from this disease. The development of novel targeted approaches to treat these cases is a pressing need. Cyclophosphamide is an intercalating agent that generates interstrand crosslinks (ICLs) and DNA damage [<a href="#hon70131-bib-0009" class="usa-link" aria-describedby="hon70131-bib-0009">9</a>]; doxorubicin is an anthracycline that stabilizes the Topoisomerase II on DNA stopping replication and causing DNA damage [<a href="#hon70131-bib-0010" class="usa-link" aria-describedby="hon70131-bib-0010">10</a>]; vincristine is a spindle poison that impairs cell division [<a href="#hon70131-bib-0011" class="usa-link" aria-describedby="hon70131-bib-0011">11</a>]; and prednisone is a glucocorticoid. Thus, genotoxic stress induced by cyclophosphamide and doxorubicin is an important part of the R‐CHOP regimen. In salvage therapies, other agents inducing DNA damages could be used including the nucleoside analog gemcitabine [<a href="#hon70131-bib-0012" class="usa-link" aria-describedby="hon70131-bib-0012">12</a>] and etodposide [<a href="#hon70131-bib-0013" class="usa-link" aria-describedby="hon70131-bib-0013">13</a>, <a href="#hon70131-bib-0014" class="usa-link" aria-describedby="hon70131-bib-0014">14</a>]. Etoposide inhibits topoisomerase II activity by forming a ternary complex with DNA inducing DNA single‐ and double‐strand breaks [<a href="#hon70131-bib-0015" class="usa-link" aria-describedby="hon70131-bib-0015">15</a>]. We have previously developed GEP‐based DNA repair signatures that allow the identification of 20% of high‐risk DLBCL patients and highlight the potential role of DNA damage response (DDR) in DLBCL drug resistance [<a href="#hon70131-bib-0016" class="usa-link" aria-describedby="hon70131-bib-0016">16</a>]. A list set of 176 genes involved in six major DNA repair pathways including base excision repair (BER), NER, mismatch repair (MMR), homologous recombination repair (HRR), non‐homologous end joining (NHEJ) and FANC pathways was analyzed using GEP data from newly diagnosed DLBCL patients treated by R‐CHOP [<a href="#hon70131-bib-0016" class="usa-link" aria-describedby="hon70131-bib-0016">16</a>]. We showed that 126 out of the 176 genes have a prognostic value with 92 genes associated with a poor outcome. For each pathway, a gene expression profile (GEP)‐based risk score was created. High FANC, NER, HRR, BER, NHEJ and MMR scores were significantly associated with poor prognosis in the two independent cohorts of patients with DLBCL underlining a potential role of DNA repair pathways in the pathogenesis and drug resistance of DLBC [<a href="#hon70131-bib-0016" class="usa-link" aria-describedby="hon70131-bib-0016">16</a>]. Genetic instability is a hallmark of cancer cells that appears at an early stage and increases during the course of the disease. One of the main causes of genetic instability is replication stress and its associated DNA damage. In fact, perturbations in DNA replication can lead to under or over‐replication, accumulation of point mutations, and chromosome instability among others, which challenge cell survival and are at the origin of malignant transformation and progression [<a href="#hon70131-bib-0017" class="usa-link" aria-describedby="hon70131-bib-0017">17</a>, <a href="#hon70131-bib-0018" class="usa-link" aria-describedby="hon70131-bib-0018">18</a>, <a href="#hon70131-bib-0019" class="usa-link" aria-describedby="hon70131-bib-0019">19</a>]. Importantly, replication stress has also been proposed as an Achilles' heel of cancer cells, since they are often addicted to DNA damage repair (DDR) pathways, which opens the door to therapeutic strategies that exploit the concept of synthetic lethality. Synthetic lethality relies on the fact that DNA lesions can be processed by different repair pathways depending on their nature. When all the pathways required to repair a particular type of lesion are not functional, the result is a catastrophic accumulation of DNA damage, either intrinsic or caused by chemotherapy, that ultimately leads to cell death. Hence, synthetic lethality provides a strong rationale for the combination of genotoxic agents with inhibitors of the main DDR pathways to treat cancer [<a href="#hon70131-bib-0020" class="usa-link" aria-describedby="hon70131-bib-0020">20</a>, <a href="#hon70131-bib-0021" class="usa-link" aria-describedby="hon70131-bib-0021">21</a>, <a href="#hon70131-bib-0022" class="usa-link" aria-describedby="hon70131-bib-0022">22</a>].</p>
<p>Here, we used previously published genome wide pooled CRISPR‐Cas9 screens data performed on 4 ABC and 4 GCB‐DLBCL cell lines [<a href="#hon70131-bib-0023" class="usa-link" aria-describedby="hon70131-bib-0023">23</a>] and assessed the enrichment/depletion score of 126 genes related to DNA repair pathways [<a href="#hon70131-bib-0016" class="usa-link" aria-describedby="hon70131-bib-0016">16</a>]. We identified the DNA repair factors <em>CHEK1</em>, <em>WEE1</em>, <em>ATR</em>, and <em>RAD51</em> as essential genes in DLBCL cell lines. DNA damage induces the activation of ATR (ataxia‐telangiectasia‐mutated‐and‐Rad3‐related kinase) and its downstream effector kinase Chk1 to arrest cell cycle progression and prevent the entry into mitosis with incompletely replicated or damaged DNA. Thus, ATR, WEE1 and Chk1 inhibitors have been developed and their therapeutic potential in cancer is being assessed [<a href="#hon70131-bib-0024" class="usa-link" aria-describedby="hon70131-bib-0024">24</a>, <a href="#hon70131-bib-0025" class="usa-link" aria-describedby="hon70131-bib-0025">25</a>, <a href="#hon70131-bib-0026" class="usa-link" aria-describedby="hon70131-bib-0026">26</a>, <a href="#hon70131-bib-0027" class="usa-link" aria-describedby="hon70131-bib-0027">27</a>, <a href="#hon70131-bib-0028" class="usa-link" aria-describedby="hon70131-bib-0028">28</a>]. Wee1 kinase is a cell cycle regulator that controls the timely entry into mitosis by inhibiting the Cdk1‐Cyclin B1 complex [<a href="#hon70131-bib-0029" class="usa-link" aria-describedby="hon70131-bib-0029">29</a>]. In addition, Wee1 is activated by Chk1 in response to DNA damage to allow DNA repair before the G2/M transition. It has been reported that treatment with Wee1 inhibitor leads to unscheduled entry into mitosis without proper DNA repair that results in mitotic catastrophe and cell death [<a href="#hon70131-bib-0030" class="usa-link" aria-describedby="hon70131-bib-0030">30</a>]. Rad51 is a recombinase involved in the repair of DSB (DNA double strand breaks) by homologous recombination (HR) that is commonly dysregulated in cancer [<a href="#hon70131-bib-0031" class="usa-link" aria-describedby="hon70131-bib-0031">31</a>]. Several Rad51 inhibitors have been evaluated or are under development to target cancer cells with promising results [<a href="#hon70131-bib-0032" class="usa-link" aria-describedby="hon70131-bib-0032">32</a>]. Importantly, previous work reported that the chemical inhibition of Chk1 and Wee1 may be a good therapeutic approach in DLBCL. On the one hand, the inhibition of Wee1 by AZD‐1775 has been shown to synergize with the CHOP chemotherapy and with radiation therapy to kill DLBCL cells [<a href="#hon70131-bib-0033" class="usa-link" aria-describedby="hon70131-bib-0033">33</a>]. On the other hand, the combination of Chk1 and Wee1 inhibitors strongly reduced Myc protein levels and led to cell death in lymphoma cell lines [<a href="#hon70131-bib-0034" class="usa-link" aria-describedby="hon70131-bib-0034">34</a>, <a href="#hon70131-bib-0035" class="usa-link" aria-describedby="hon70131-bib-0035">35</a>]. Of note, the combination of both inhibitors also led to increased γH2AX levels in seven DLBCL cell lines, indicative of DNA damage induction [<a href="#hon70131-bib-0035" class="usa-link" aria-describedby="hon70131-bib-0035">35</a>]. Similarly, the response of non‐GCB DLBCL cells to ATR and Wee1 inhibitors was shown to be linked to replication stress [<a href="#hon70131-bib-0036" class="usa-link" aria-describedby="hon70131-bib-0036">36</a>]. Furthermore, ATRi elimusertib demonstrated ati‐lymphoma activity in vitro and in vivo and synergized with PI3K inhibitor [<a href="#hon70131-bib-0037" class="usa-link" aria-describedby="hon70131-bib-0037">37</a>, <a href="#hon70131-bib-0038" class="usa-link" aria-describedby="hon70131-bib-0038">38</a>]. Taken together, these data point at a great interest of DNA repair factors as chemotherapeutic targets in DLBCL.</p>
<p>Synthetic lethality occurs when mutations in two genes simultaneously result in cell death, while individual mutations in either gene alone allow cells to survive [<a href="#hon70131-bib-0039" class="usa-link" aria-describedby="hon70131-bib-0039">39</a>]. Years later, this concept was adapted for cancer research, ultimately culminating in the development and approval of novel therapeutic approaches [<a href="#hon70131-bib-0040" class="usa-link" aria-describedby="hon70131-bib-0040">40</a>]. Drug‐drug synthetic lethality was designed to overcome inherent drug resistance, which frequently occurs when drug treatment triggers feedback mechanisms that activate the targeted pathway or compensatory parallel pathways [<a href="#hon70131-bib-0039" class="usa-link" aria-describedby="hon70131-bib-0039">39</a>, <a href="#hon70131-bib-0040" class="usa-link" aria-describedby="hon70131-bib-0040">40</a>]. Based on these results, we investigated the effect of small molecules targeting DNA replication stress and DNA repair mechanisms, alone or in combination with the R‐CHOP genotoxic agents, cyclophosphamide and doxorubicin. Moreover, we found three synthetic lethal combinations: (1) cyclophosphamide plus the Chk1/2 inhibitor PF‐477736, (2) cyclophosphamide and the ATR inhibitor AZD‐6738, and (3) doxorubicin with the DNA‐PK inhibitor NU‐7441. Co‐treatment with these molecules led to cell death in cell lines and primary DLBCL cells from patients by increasing DNA damage more efficiently than genotoxic agents alone. Our findings open new perspectives for therapeutic approaches exploiting the synthetic lethality of genotoxic agents with DNA repair inhibitors to improve the therapeutic outcome of patients with DLBCL.</p></section><section id="hon70131-sec-0020"><h2 class="pmc_sec_title">2. Materials and Methods</h2>
<section id="hon70131-sec-0030"><h3 class="pmc_sec_title">2.1. Drugs and Inhibitors</h3>
<p>The compounds used in this study are PJ‐34 (PARP1/2 inhibitor; 3255 Tocris Bioscience), NU‐7441 (DNAPK inhibitor; S2638 Selleckchem), KU‐55933 (ATM inhibitor; S1092 Selleckchem), PF‐477736 (CHK1/2 inhibitor; S2904 Selleckchem), AZD‐6738 (ATR inhibitor; S7693 Selleckchem), MK‐8776 (CHK1 inhibitor; S2735 Selleckchem), AZD‐1775 (Wee1 inhibitor; S1525 Selleckchem), MP‐470 (Rad51 inhibitor; S1244 Selleckchem), Gemcitabine (nucleic acid synthesis inhibitor; S1714 Selleckchem), Doxorubicin and Etoposide (topoisomerase II inhibitors; D1515 Sigma Aldrich and S1225 Selleckchem, respectively), Mafosfamide (nitrogen mustard, active form of 4‐OH‐Cyclophosphamide; SC‐211761 Santa Cruz Biotechnology.</p></section><section id="hon70131-sec-0040"><h3 class="pmc_sec_title">2.2. Culture of DLBCL Cell Lines</h3>
<p>The 16 DLBCL cell lines from the 2 subtypes: ABC‐DLBCL (NU‐DUL‐1, OCI‐LY3, RI‐1, U‐2932) and GCB‐DBCL (DB, DOHH‐2, HT, NU‐DHL‐1, OCI‐LY1, OCI‐LY7, OCI‐LY19, SU‐DHL‐4, SU‐DHL‐5, SU‐DHL‐6, SU‐DHL‐10, WSU‐DLCL‐2) were purchased from the DSMZ (Leibniz‐Institut DSMZ ‐ Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Germany). Cells were maintained in RPMI‐1640 (Gibco, Invitrogen), supplemented with 10% fetal bovine serum (PAA laboratory GmbH) for U2932, SUDHL‐4, HT, DOHH2, SUDHL‐10, RI‐1, and WSU‐DLCL‐2 cell lines, and 20% FBS OCI‐LY3, DB, SUDHL‐5, NU‐DHL‐1, NU‐DUL‐1 and SU‐DHL‐6, cell lines. OCI‐LY1, OCI‐LY7 was cultured in IMDM (Gibco, Invitrogen), supplemented with 20% fetal bovine serum and OCI‐LY19 was cultured in MEM alpha modified (Gibco, Invitrogen), supplemented with 20% fetal bovine serum. Cultures were maintained at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>.</p></section><section id="hon70131-sec-0050"><h3 class="pmc_sec_title">2.3. Culture and Treatment of Primary Cells and FACS</h3>
<p>Lymph node samples were collected after patients' written informed consent in accordance with the Declaration of Helsinki and institutional research board approval from Montpellier University Hospital (HEMODIAG_2020 cohort (ID‐RCB: 2011‐A00924‐37, <a href="https://clinicaltrials.gov/ct2/show/NCT02134574" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02134574</a>)). Frozen cells in 10% DMSO from lymph nodes of 5 patients with DLBCL banked in the HEMODIAG_2020 collection were thawed, washed and qualified by flow cytometry.</p>
<p>For drug sensitivity assays, primary cells were cultured for 96 h in Gibco Iscove's MDM (Glutamax) medium (#31980‐022) with 20% FBS with antibiotics‐antimycotics 1X (Gibco Penicillin‐streptomycin‐amphotericin B 100X, #15240‐096) at a density of 0.5 × 10^6 Cell/mL with 50 ng/mL of histidine‐tagged CD40 L (R&amp;D System, 2706‐CL) and 5 µg/mL of anti‐histidine antibody (R&amp;D System, MAB050) and pyruvate 1X (Gibco pyruvate 100X, # 1136‐039).</p>
<p>Total cells were counted with trypan blue and stained with the panel CD45 V500 (BD, #560777), Ig Kappa FITC (Dako, F0434), CD19 PE‐Cy7 (BD, #341113), Ig Lambda PE (Dako, R0437), CD3 APC‐H7 (BD, #641415), CD10 APC (BD, #332777) and CD20 V450 (BD, #655872) and analyzed by flow cytometry (Canto II cytometer, Becton Dickinson).</p>
<p>The percentage of tumor cells (CD19+, CD45+, CD20+, Igκ or Igλ, CD10+ (if GCB subset)), non‐tumor cells (CD45+, CD19‐), and T cells (CD45+, CD3+) in each sample was determined by flow cytometry before and after treatment.</p></section><section id="hon70131-sec-0060"><h3 class="pmc_sec_title">2.4. Loss‐Of‐Function CRISPR‐Cas9 Genetic Screens</h3>
<p>The genome‐wide CRISPR‐Cas9 loss‐of‐function screening data were collected from Phelan et al. [<a href="#hon70131-bib-0023" class="usa-link" aria-describedby="hon70131-bib-0023">23</a>] and include 4 GCB and 4 ABC DLBCL cell lines. A CRISPR Screen Score (CSS) for DNA repair genes was calculated as previously described in the same work. CSS is a normalized value of toxicity considering all 4 sgRNA for each gene present in the CRISPR library. The results were also validated using publicly available database from Dependency Map portal (Broad Institute, <a href="http://www.depmap.org/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.depmap.org</a>) [<a href="#hon70131-bib-0041" class="usa-link" aria-describedby="hon70131-bib-0041">41</a>].</p></section><section id="hon70131-sec-0070"><h3 class="pmc_sec_title">2.5. Determination of the IC50 of Drugs and Inhibitors by Cell Viability Assays</h3>
<p>DLBCL‐derived cell lines were cultured for 4 days in 96‐well flat‐bottom microtiter plates in the presence or absence of the different inhibitors as decribed [<a href="#hon70131-bib-0042" class="usa-link" aria-describedby="hon70131-bib-0042">42</a>]. The number of viable cells in culture was determined using the CellTiter‐Glo Luminescent Cell Viability Assay (G7573 Promega) using a Centro LB 960 luminometer (Berthold Technologies). This test is based on quantitation of the intracellular ATP present, which signals the presence of metabolically active cells. Data are expressed as the mean percentage of six technical replicates, normalized to the untreated control.</p></section><section id="hon70131-sec-0080"><h3 class="pmc_sec_title">2.6. Statistical Analysis</h3>
<p>Statistical tests were performed with Graphpad Prism V7 (Graphpad Software) and R i386 V3.4.0 software (R Fondation). Inhibitory concentration 50 (IC50) was calculated with the four‐parameter logistic regression formulA, as previously described [<a href="#hon70131-bib-0042" class="usa-link" aria-describedby="hon70131-bib-0042">42</a>, <a href="#hon70131-bib-0043" class="usa-link" aria-describedby="hon70131-bib-0043">43</a>].</p>
<p>Significant synergy and combination indexes (CI) were calculated using the Chou‐Talalay formula [<a href="#hon70131-bib-0044" class="usa-link" aria-describedby="hon70131-bib-0044">44</a>] as previously described [<a href="#hon70131-bib-0043" class="usa-link" aria-describedby="hon70131-bib-0043">43</a>, <a href="#hon70131-bib-0045" class="usa-link" aria-describedby="hon70131-bib-0045">45</a>].</p></section></section><section id="hon70131-sec-0090"><h2 class="pmc_sec_title">3. Results</h2>
<section id="hon70131-sec-0100"><h3 class="pmc_sec_title">3.1. Analysis of the Therapeutic Interest of Drugs Targeting the DDR and Genotoxic Agents in the Treatment of DLBCL</h3>
<p>In an effort to better understand the role of the DNA damage repair (DDR) pathways in DLBCL [<a href="#hon70131-bib-0016" class="usa-link" aria-describedby="hon70131-bib-0016">16</a>] and their therapeutic interest, we mined previously published genome wide pooled CRISPR‐Cas9 screens data performed on 4 ABC and 4 GCB‐DLBCL cell lines [<a href="#hon70131-bib-0023" class="usa-link" aria-describedby="hon70131-bib-0023">23</a>] and assessed the enrichment/depletion score of 126 genes related to DNA repair pathways [<a href="#hon70131-bib-0016" class="usa-link" aria-describedby="hon70131-bib-0016">16</a>]. A negative score is associated with genes whose inactivation leads to cell death. We identified that sgRNAs targeting <em>ATR</em>, <em>CHEK1</em>, <em>WEE1</em>, ATR, RPA3 and <em>RAD51</em> were the most depleted indicating essentiality in DLBCL cell lines (Figure <a href="#hon70131-fig-0001" class="usa-link">1</a>).We did not identified a specific dependency for ABC or GCB cell lines except for APEX2 that is only essential in ABC DLBCL cell lines. These results were confirmed using independent data from the DepMap portal (Figure <a href="#hon70131-sup-0002" class="usa-link">S1</a>).</p>
<figure class="fig xbox font-sm" id="hon70131-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/12374179/51419ea4c3e5/HON-43-e70131-g001.jpg" loading="lazy" id="jats-graphic-1" height="986" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/hon70131-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>DDR genes are essential genes in DLBCL cells. Cumulative plot showing the dependency scores calculated using data from 8 cell lines [<a href="#hon70131-bib-0023" class="usa-link" aria-describedby="hon70131-bib-0023">23</a>]. A negative score indicates that gene is more likely to essential in DLBCL cell lines.</p></figcaption></figure><p>Thus, we investigated the therapeutic interest of 8 DNA repair inhibitors targeting ATM (KU‐55933), ATR (AZD‐6738), Chk1/2 (PF‐477736), Chk1 (AZD‐8776), Wee1 (AZD‐1775), Rad51 (MP‐470), DNA‐PK (NU‐7441), and PARP (PJ34). As controls, the response to 4 conventional chemotherapy genotoxic agents (gemcitabine, 4‐OH‐Cyclophosphamide, etoposide, and doxorubicin) was assessed in 16 DLBCL cell lines (Figure <a href="#hon70131-fig-0002" class="usa-link">2</a> and Supporting Information <a href="#hon70131-sup-0001" class="usa-link">S1</a>). As expected, the 4 genotoxic agents presented a dose‐response in the order of nanomolar. Of them, the most genotoxic one was the nucleoside analog gemcitabine, which could be used as salvage therapy in relapsed/refractory DLBCL [<a href="#hon70131-bib-0012" class="usa-link" aria-describedby="hon70131-bib-0012">12</a>]. Inhibitors for DNA repair factors targeting Wee1 (AZD_1775), Chk1 (AZD_8776) and ATR (AZD_6738) showed a dose‐response ratio in the nanomolar order, while the rest of them presented a median IC50 in the micromolar range (Figure <a href="#hon70131-fig-0002" class="usa-link">2</a> and Supporting Information <a href="#hon70131-sup-0001" class="usa-link">S1</a>). In a previous work, we developed GEP‐based DNA repair signatures allowing the identification of high‐risk DLBCL patients and underlining the potential role of DDR in DLBCL drug resistance [<a href="#hon70131-bib-0016" class="usa-link" aria-describedby="hon70131-bib-0016">16</a>]. For each pathway, a gene expression profile (GEP)‐based risk score was created. High FANC, NER, HRR, BER, NHEJ and MMR scores associated with overexpression of genes involved in these pathways were significantly associated with poor prognosis in independent cohorts of patients with DLBCL. Of interest, we identified that high HRR and BER GEP‐based scores are associated with sensitivity to etoposide in the investigated cell lines (<em>r</em> = −0.58 and <em>r</em> = −0.70, respectively, <em>p</em> &lt; 0.05). Furthermore a significant negative correlation between FANC score and the response to the ATR inhibitor AZD‐6738 (<em>r</em> = −0.58, <em>p</em> &lt; 0.05) was also identified. These data indicate that high‐risk DLBCL patients identified with GEP‐based FANC and HRR/BER scores may benefit from treatment by ATR inhibitors and etoposide, respectively (Figure <a href="#hon70131-sup-0003" class="usa-link">S2</a>). However, high HRR score is associated with resistance to PARPi and high NHEJ score value coorelated with high IC50 of DNA‐PKi and ATMi (Figure <a href="#hon70131-sup-0003" class="usa-link">S2</a>).</p>
<figure class="fig xbox font-sm" id="hon70131-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/12374179/446f616b0c20/HON-43-e70131-g003.jpg" loading="lazy" id="jats-graphic-3" height="594" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/hon70131-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Characterization of IC<sub>50</sub> of 10 drugs targeting DNA repair and 4 genotoxic agents in DLBCL cell lines. DLBCL cell lines were cultured for 96 h with culture medium (control) and increasing concentrations of the indicated drugs. The IC50 for each drug and each cell line was calculated with the four parameters logistic regression method. The IC50 represented here is the mean of at least three independent experiments.</p></figcaption></figure><p>In conclusion, our analyses show that deregulation of the DDR is a major mechanism for replicative stress adaptation and resistance to chemotherapy in DLBCL that could represent a therapeutic target.</p></section><section id="hon70131-sec-0110"><h3 class="pmc_sec_title">3.2. Pharmacological Inhibition of ATR, Chk1 and Wee1 Induces Cell Death in DLBCL Cell Lines</h3>
<p>The CRISPR‐Cas9 screening data identified <em>ATR</em>, <em>CHEK1</em> and <em>WEE1</em> as essential genes in DLBCL cell lines (Figure <a href="#hon70131-fig-0001" class="usa-link">1</a> and Figure <a href="#hon70131-sup-0002" class="usa-link">S1</a>). Accordingly, the chemical inhibitors of ATR, Chk1 and Wee1 showed the most potent cytotoxicity in DLBCL cells correlating the CRISPR screen results (Figure <a href="#hon70131-fig-0002" class="usa-link">2</a>). Thus, we aimed to further characterize the toxicity of AZD‐6738 (ATRi), PF‐477736 (Chk1i) and AZD‐1775 (Wee1i) using the cell lines OCI‐LY3 and DB, which belong to the ABC‐ and GCB‐DLBCL subtypes, respectively. PF‐477736 Chk1i was selected since it was reported to inhibit proliferation in lymphoma cell lines in vitro [<a href="#hon70131-bib-0046" class="usa-link" aria-describedby="hon70131-bib-0046">46</a>] and in MYC driven lymphoma model [<a href="#hon70131-bib-0047" class="usa-link" aria-describedby="hon70131-bib-0047">47</a>]. Treatment with the inhibitors of ATR, Chk1 and Wee1 induced a significant increase in PARP cleavage, indicative of apoptosis in the 2 lines (Figure <a href="#hon70131-fig-0003" class="usa-link">3A</a>). This increase in cell death correlated with a decrease in proliferation marked by reduced S phase in both cell lines, and accumulation in G2/M phase for DB cells and in G0/G1 phase for OCI‐LY3 cells (Figure <a href="#hon70131-fig-0003" class="usa-link">3B</a>). Interestingly, Chk1 and Wee1 inhibitors led to a significant increase of γH2AX positive cells, indicating DNA damage (Figure <a href="#hon70131-fig-0003" class="usa-link">3C</a>). On the other hand, the genotoxic agents etoposide, doxorubicin and 4‐OH‐Cyclophosphamide, induced a marked increase in apoptosis and cell cycle arrest, also characterized by S‐phase arrest and G0/G1 or G2/M accumulation depending on the cell line (Figure <a href="#hon70131-sup-0004" class="usa-link">S3AB</a>). Doxorubicin caused DNA damage in both cell lines as determined by γH2AX staining, while 4‐OH‐Cyclophosphamide did so only in the DB cell line and etoposide did not cause significant DNA damage in either cell line (Figure <a href="#hon70131-sup-0004" class="usa-link">S3C</a>). Moreover, Chk1 and Wee1 inhibitors iduced caspase and PARP cleavage in DB together with phosphorylation together with DNA damage monitored by γH2AX induction in DB cell line (Figure <a href="#hon70131-sup-0005" class="usa-link">S4</a>). ATRi iduced Chk2 and p53 phosphorylation in DB cell line (Figure <a href="#hon70131-sup-0005" class="usa-link">S4</a>). In OCI‐LY3, ATRi, Chk1i and Wee1i induced caspase 8 cleavage and γH2AX induction (Figure <a href="#hon70131-sup-0005" class="usa-link">S4</a>). These results suggest that chemical inhibition of the DNA repair factors ATR, Chk1 and Wee1 or treatment with the genotoxic agents doxorubicin and 4‐OH‐Cyclophosphamide induce replication stress, leading to DNA damage and cell cycle arrest in S‐phase, which in combination may result in significant synergistic effects.</p>
<figure class="fig xbox font-sm" id="hon70131-fig-0003"><h4 class="obj_head">FIGURE 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/12374179/7d4246452828/HON-43-e70131-g007.jpg" loading="lazy" id="jats-graphic-5" height="870" width="709" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/hon70131-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Effect of DDR inhibitors on apoptosis, cell cycle and DNA damage induction in DLBCL cells. (A, B) Cells were treated for 72 h. (A) Apoptotic cells (positive for cleaved‐PARP‐PE staining) were quantified by flow cytometry. (B) Cell cycle was analyzed using flow cytometry. S phase was monitored using BrdU incorporation and anti‐BrdU antibody. DNA content was stained with 4′,6‐diamidino‐2‐phenylindole (DAPI). Histograms represent the mean percentage and SEM of each cell cycle phase of three independent experiments. *<em>p</em> &lt; 0.05, **<em>p</em> &lt; 0.01 with paired Student t test. (C) Cells were incubated with AZD_6738, PF_477736 or AZD_1775 for 24H. All data in this figure represent the mean +/− SEM of three independent experiments. Statistical significance was tested using <em>t</em>‐test of pairs. *<em>p</em> &lt; 0.05, **<em>p</em> &lt; 0.01.</p></figcaption></figure></section><section id="hon70131-sec-0120"><h3 class="pmc_sec_title">3.3. ATR, Chk1 and DNA‐PK Inhibitors Synergize With Genotoxic Agents to Kill DLBCL Cells</h3>
<p>Since deregulation of DNA repair pathways plays a crucial role in drug resistance in many cancers [<a href="#hon70131-bib-0048" class="usa-link" aria-describedby="hon70131-bib-0048">48</a>], including DLBCL, we sought to identify new synthetic lethal combinations between inhibitors of DNA repair factors and genotoxic agents. To this end, we combined the IC20 of inhibitors of eight DNA repair factors (PF‐47736 (Chk1i), NU‐7441 (DNA‐PKi), AZD‐1775 (Wee1i), AZD‐6738 (ATRi), MK‐8776 (Chk1/2i), MP‐470 (Rad51i), KU‐55933 (ATMi), PJ34 (PARP1/2i)) with doxorubicin, etoposide and 4‐OH‐Cyclophosphamide, using the U2932 cell line (ABC‐DLBCL) that is one of the most resistant to the different DDR inhibitors. We calculated the combination index (CI) for each DDR inhibitor with each genotoxic drug according to the Chou‐Talalay method [<a href="#hon70131-bib-0044" class="usa-link" aria-describedby="hon70131-bib-0044">44</a>]. A CI &lt; 0.7 was considered as a potential synthetic lethal interaction, whereas 0.7 &lt; CI &lt; 1 was considered as a potentially synergistic combination (Supporting Information <a href="#hon70131-sup-0001" class="usa-link">S1</a>). Applying a standard threshold of 2 standard deviations below the IC50 of the genotoxic agent alone [<a href="#hon70131-bib-0049" class="usa-link" aria-describedby="hon70131-bib-0049">49</a>], four DDR inhibitors were found to be synthetic lethal or synergistic with genotoxic agents, namely the Chk1 inhibitor PF‐477736, the ATR inhibitor AZD‐6738, and the ATM inhibitor KU‐55933 with both 4‐OH‐Cyclophosphamide and etoposide, and the DNA‐PK inhibitor NU‐7441 with doxorubicin. We then tested these combinations using four cell lines: DB (GCB‐DLBCL), SUDHL10 (GCB‐DLBCL), U2932 (ABD‐DLBCL) and OCI‐LY3 (ABC‐DLBCL), which are among the most resistant to conventional genotoxic agents. First, we observed a significant decrease in the IC50 of 4‐OH‐Cyclophosphamide when combined with AZD‐6738 (ATRi) and PF‐477736 (Chki), and of doxorubicin when combined with NU‐7441 (DNA‐PKi) (Figure <a href="#hon70131-fig-0004" class="usa-link">4A,B</a>). Importantly, the CI calculation of each drug combination for each cell line confirmed a strong synergistic effect in all cases, except for the combination of Chk1i with 4‐OH‐Cyclophosphamide for the DB cell line (Figure <a href="#hon70131-fig-0004" class="usa-link">4C</a>).</p>
<figure class="fig xbox font-sm" id="hon70131-fig-0004"><h4 class="obj_head">FIGURE 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/12374179/fdcb05b813f3/HON-43-e70131-g004.jpg" loading="lazy" id="jats-graphic-7" height="908" width="709" alt="FIGURE 4"></p>
<div class="p text-right font-secondary"><a href="figure/hon70131-fig-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Synthetic lethal combination of DDR inhibitors with cyclophosphamide and doxorubicin in DLBCL cells. (A) DLBCL cell lines were treated with 4‐OH‐Cyclophosphamide in combination with IC20 of ATR inhibitor (AZD_6738) or IC20 of CHK1 inhibitor (PF_477736). The combination of Doxorubicin with the IC20 of DNA‐PK inhibitor (NU_7441) was also investigated in four DLBCL cell lines (DB, OCI‐LY3, U2932 and SUDHL10). IC50 were calculated after viability assessment by CellTiter‐Glo luminescent cell viability assay. Results are representative of three independent experiments. Significant synergy and combination index (CI) are calculated by the method of Chou Talalay. (B) Inhibitory concentration 50 of 4‐OH‐Cyclophosphamide in combination with IC20 of ATR inhibitor (AZD_6738) and CHK1 inhibitor (PF_477736). Inhibitory concentration 50 of doxorubicin combined with IC20 of DNA‐PK inhibitor (NU_7441). IC50 were calculated after viability assessment by CellTiter‐Glo luminescent cell viability assay. Results are representative of three independent experiments. (C) Significant synergy and combination index (CI) are calculated by the method of Chou Talalay. Normalized IC50 isobolograms showing the drug combination effect in the DLBCL cell lines. Statistical significance was tested using <em>t</em>‐test for pairs. *<em>p</em> &lt; 0.05, **<em>p</em> &lt; 0.01.</p></figcaption></figure><p>We further analyzed the effect of these synergistic drug combinations on cell viability using the U2932 and DB cell lines. In U2932 cells, co‐treatment with 4‐OH‐Cyclophosphamide plus ATR/Chk1 inhibitors induced a significant increase in Annexin V‐positive cells, indicative of apoptosis, and an alteration in cell cycle distribution characterized by a decrease in G0/G1 population and an accumulation in the G2/M phase (Figure <a href="#hon70131-fig-0005" class="usa-link">5A</a>, upper panels). However, in the DB cell line, only the combination of 4‐OH‐Cyclophosphamide with the ATRi significantly increased the number of apoptotic cells and the inhibition of proliferation (Figure <a href="#hon70131-fig-0005" class="usa-link">5A</a>, lower panels). Similar phenotypes were observed when combining doxorubicin with DNA‐PKi in both cell lines (Figure <a href="#hon70131-fig-0005" class="usa-link">5B</a>). Mechanistically, co‐treatment with 4‐OH‐Cyclophosphamide and ATRi, or doxorubicin plus DNA‐PKi, increased the level of γH2AX in both cell lines (Figure <a href="#hon70131-fig-0006" class="usa-link">6A,B</a>). Similarly, the level of phosphorylation of RPA2 at Serines 4 and 8 (pRPA2 S4 S8), another marker of replication stress [<a href="#hon70131-bib-0042" class="usa-link" aria-describedby="hon70131-bib-0042">42</a>], was increased by treatment with 4‐OH‐Cyclophosphamide, ATRi or Chk1i, and was further enhanced by the combination of the genotoxic agent with Chk1i (Figure <a href="#hon70131-fig-0006" class="usa-link">6C</a>). Moreover, western bot analysis were perfomed to assess the effects of the ccombinations on the epression levels of several well‐known factors controlling apoptosis, cell cycle progression and DDR (Figure <a href="#hon70131-sup-0006" class="usa-link">S5</a>). To further characterize the impact of the drug combination on the induction of replication stress induction, we performed DNA fiber analysis. Treatment with 4‐OH‐Cyclophosphamide, AZD‐6738 (ATRi) or PF‐477736 (Chk1i) strongly reduced replication fork speed (Figure <a href="#hon70131-sup-0007" class="usa-link">S6</a>). Moreover, the combination of 4‐OH‐Cyclophosphamide with either inhibitor further impaired fork progression (Figure <a href="#hon70131-sup-0007" class="usa-link">S6</a>). We also investigated the combination of ATRi (AZD‐6738), CHK1i (PF‐477736) and ATMi (KU‐55933) IC20 with etoposide. However, no synthetic lethality or significant synergy was identified in the two DLBCL cell lines tested (Figure <a href="#hon70131-sup-0008" class="usa-link">S7</a>).</p>
<figure class="fig xbox font-sm" id="hon70131-fig-0005"><h4 class="obj_head">FIGURE 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/12374179/e918b4394d1a/HON-43-e70131-g002.jpg" loading="lazy" id="jats-graphic-9" height="1008" width="709" alt="FIGURE 5"></p>
<div class="p text-right font-secondary"><a href="figure/hon70131-fig-0005/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Synthetic lethal combinations enhance apoptosis, induce cell cycle defect and activate DDR. (A, B) U2932 and DB cell lines were treated as indicated with IC20 of each drug (U2932 cell line: Cyclophosphamide 1 µM, <a href="https://www.ncbi.nlm.nih.gov/nuccore/PF477736" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">PF477736</a> 0.31, AZD‐6738 1.01 µM, Doxorubicin 30 nM, NU7441 3.1 µM; DB cell line: Cyclophosphamide: 0.8 μM, <a href="https://www.ncbi.nlm.nih.gov/nuccore/PF477736" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">PF477736</a> 0.39, AZD‐6738 3.13 µM, Doxorubicin 30 nM, NU7441 3.1 µM). Apoptosis was studied by AnnexinV‐PE staining and cell cycle was studied using BrdU incorporation and DAPI after 72H of treatment. Data are the mean ± SD of three independent experiments. Statistical significance was tested using <em>t</em>‐test for pairs. *<em>p</em> &lt; 0.05, **<em>p</em> &lt; 0.01, ***<em>p</em> &lt; 0.001, NS: non‐significant.</p></figcaption></figure><figure class="fig xbox font-sm" id="hon70131-fig-0006"><h4 class="obj_head">FIGURE 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/12374179/9b428f0c55ca/HON-43-e70131-g005.jpg" loading="lazy" id="jats-graphic-11" height="819" width="709" alt="FIGURE 6"></p>
<div class="p text-right font-secondary"><a href="figure/hon70131-fig-0006/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Synthetic lethal combinations induce DNA damage. (A) U2932 and (B) DB cell lines were treated as indicated on the Figure. Double strand breaks were studied by γH2A.X staining in in BrdU positive cells. Cells were analyzed by flow cytometry at 72H after treatment. Data are the mean ± SD of three independent experiments. Statistical significance was tested using <em>t</em>‐test for pairs. *<em>p</em> &lt; 0.05, **<em>p</em> &lt; 0.01, ***<em>p</em> &lt; 0.001, NS: non‐significant. (C) U2932 cells were treated as indicated (IC50 of each drug) during 24H. At the end of the treatment, cells were fixed for immunofluorescence with 4% PFA for 10 min at RT. Foci of phospho‐RPA2 S4‐S8 were analyzed, S phase was stained by EdU and click‐it reaction and nuclei were satined with DAPI. The percentage of cells with more than 10 phospho‐RPA2 S4‐S8 foci per cell is displayed in the histogram. At least 300 cells were counted for each group. Statistical difference was tested using a Fisher's exact test. *<em>p</em> &lt; 0.05, **<em>p</em> &lt; 0.01, ***<em>p</em> &lt; 0.001, ****<em>p</em> &lt; 0.0001. Results are representative of three independent experiments. NS, non‐significant.</p></figcaption></figure><p>Taken together, these results underscore that the combination of inhibitors targeting the DDR factors ATR, Chk1 and DNA‐PK with 4‐OH‐Cyclophosphamide or doxorubicin synergizes to induce DNA replication fork stalling, leading to increased levels of DNA damage and genetic instability, which in turn leads to cell death by apoptosis.</p></section><section id="hon70131-sec-0130"><h3 class="pmc_sec_title">3.4. ATR, Chk1 and DNA‐PK Inhibitors Synergize With Genotoxic Agents to Induce Toxicity in Primary DLBCL Cells From Patients</h3>
<p>To confirm the therapeutic potential of the identified synthetic lethal combinations, we tested the effect of the combination of 4‐OH‐Cyclophosphamide with AZD‐6738 (ATRi) and PF‐477736 (Chk1i), and of doxorubicin with NU‐7441 (DNA‐PKi) on cell viability in primary lymph node (LN) cells coming from 6 DLBCL patients (Supporting Information <a href="#hon70131-sup-0001" class="usa-link">S1</a>).</p>
<p>Primary DLBCL cells were co‐cultured with the non‐malignant LN microenvironment completed with 50 ng/mL of CD40 L histidine‐tagged and anti‐histidine antibodies. Primary cell cultures were treated with the drug combinations for 96 h, then counted and the fractions of viable DLBCL cells (CD19+, <em>κ</em> or <em>λ</em> +) and non‐malignant cells were determined by flow cytometry. All co‐treatments significantly reduced the number of tumor cells in cell cultures more than the genotoxic agents alone (Figure <a href="#hon70131-fig-0007" class="usa-link">7</a>), confirming the synergy/synthetic lethal results obtained with DLBCL cell lines. Furthermore, the toxicity was higher in DLBCL cells compared to non‐malignant cells except for the combination of DNA‐PK/doxorubicin, which showed similar toxicity in both compartments (Figure <a href="#hon70131-sup-0009" class="usa-link">S8</a>). Altogether, these data suggest that the combination of ATRi or CHK1i with cyclophosphamide could be of therapeutic value in high‐risk or relpased/refractory DLBCL patients.</p>
<figure class="fig xbox font-sm" id="hon70131-fig-0007"><h4 class="obj_head">FIGURE 7.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/12374179/7ba519bd50d9/HON-43-e70131-g006.jpg" loading="lazy" id="jats-graphic-13" height="982" width="709" alt="FIGURE 7"></p>
<div class="p text-right font-secondary"><a href="figure/hon70131-fig-0007/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Synthetic lethal combinations have toxic effects on primary DLBCL cells. Mononuclear cells from six patients with DLBCL were cultured for 4 days in the presence of CD40 L. DLBCL cells were treated as indicated: (A) AZD‐6738, (B) PF‐477736, and (C) NU‐7441. At day 4 of culture, the viability and total cell count were assessed and the percentage of viable DLBCL cells was determined by flow cytometry. Results are median values from six different patients. Statistical significance was tested using <em>t</em>‐test for pairs. *<em>p</em> &lt; 0.05, **<em>p</em> &lt; 0.01, ***<em>p</em> &lt; 0.001, NS: non‐.significant.</p></figcaption></figure></section></section><section id="hon70131-sec-0140"><h2 class="pmc_sec_title">4. Discussion</h2>
<p>Tumor heterogeneity is one of the major barriers to the development of successful cancer therapies. Activation of alternative DDR pathways to counteract therapies can lead to drug resistance. In this study, taking advantage of CRISPR‐Cas9 sreening data in DLBCL lines and focusing on genes encoding DDR factors, we identified specific dependencies on <em>CHEK1</em>, <em>WEE1</em>, <em>ATR</em>, and <em>RAD51</em> in both GCB and ABC cell line models. The combination of ATR, Chk1 and DNA‐PK inhibitors with doxorubicin or cyclophosphamide demonstrates synergistic toxicities in DLBCL cells in association with DNA damage, inhibition of proliferation and apoptosis induction.</p>
<p>We previously reported that high‐risk DLBCL patients are characterized by deregulation of DNA repair gene expression in association with a poor outcome after R‐CHOP treatment [<a href="#hon70131-bib-0016" class="usa-link" aria-describedby="hon70131-bib-0016">16</a>, <a href="#hon70131-bib-0050" class="usa-link" aria-describedby="hon70131-bib-0050">50</a>]. These data support the idea that inhibitors of DNA damage signaling and DNA repair are of potential therapeutic interest in DLBCL. We found that DLBCL cells overexpressing genes involved in the FANC pathway [<a href="#hon70131-bib-0005" class="usa-link" aria-describedby="hon70131-bib-0005">5</a>] are more sensitive to ATRi, whereas overexpression of HRR or BER genes is associated with higher sensitivity to etoposide (Figure <a href="#hon70131-sup-0003" class="usa-link">S2</a>). More recently, it was reported that DLBCL expressing LMO2 have deficient HRR DNA repair and are more sensitive to PARP1/2 inhibitors [<a href="#hon70131-bib-0051" class="usa-link" aria-describedby="hon70131-bib-0051">51</a>]. Furthermore, PARPi synergize with chemotherapy in LMO2 positive tumor cells [<a href="#hon70131-bib-0051" class="usa-link" aria-describedby="hon70131-bib-0051">51</a>]. Here, we identified that DLBCL cell lines characterized by HRR gene overexpression [<a href="#hon70131-bib-0016" class="usa-link" aria-describedby="hon70131-bib-0016">16</a>] are more resistant to PARPi whereas NHEJ gene overexpression [<a href="#hon70131-bib-0016" class="usa-link" aria-describedby="hon70131-bib-0016">16</a>] is associated with resistance to DNA‐PK and ATM inhibitors (Figure <a href="#hon70131-sup-0003" class="usa-link">S2</a>). Furthermore, recent data demonstrated that CDKN2A inactivation determines sensitivity to ATRi [<a href="#hon70131-bib-0037" class="usa-link" aria-describedby="hon70131-bib-0037">37</a>]. The characterization of the CDKN2A status may be important to guide the use of ATRi in lymphoma cells. The interest of DDR pathway GEP‐based signatures in DLBCL was recently validated to develop more personalized treatments in patients who have relapsed after frontline therapies [<a href="#hon70131-bib-0016" class="usa-link" aria-describedby="hon70131-bib-0016">16</a>, <a href="#hon70131-bib-0050" class="usa-link" aria-describedby="hon70131-bib-0050">50</a>, <a href="#hon70131-bib-0052" class="usa-link" aria-describedby="hon70131-bib-0052">52</a>]. Furthermore, MYC deregulation generate replicative stress and DDR in DLBCL cells [<a href="#hon70131-bib-0053" class="usa-link" aria-describedby="hon70131-bib-0053">53</a>]. According to that, synthetic lethal approaches have been developed to target essential signaling pathways downstream of MYC. Chk1 and Wee1 inhibitors have been proposed as a new therapeutic approach for DLBCL with MYC deregulation [<a href="#hon70131-bib-0053" class="usa-link" aria-describedby="hon70131-bib-0053">53</a>]. Through an integrative gene expression and genetic alteration analysis, Reddy et al. revealed dysregulated DNA damage and replication genes, including Chromodomain‐Helicase‐DNA‐binding protein 1 (CHD1), ATR, and E1A‐binding protein p300 (EP300) as drivers of DLBCL [<a href="#hon70131-bib-0054" class="usa-link" aria-describedby="hon70131-bib-0054">54</a>]. Different DLBCL genetic subgroups with specific genotypic, epigenetic, and clinical characteristics were identified including a particular subgroup in EZH2 mutated patients associated with a complex deregulation of the DDR network [<a href="#hon70131-bib-0006" class="usa-link" aria-describedby="hon70131-bib-0006">6</a>].</p>
<p>Here, we report DLBCL‐selective synergistic killing by ATR, Chk1 and DNA‐PK inhibitors in association with conventional chemotherapy agents. Synthetic lethality strategies have shown promise in solid tumors by targeting specific genetic vulnerabilities. Two notable examples are the use of PARP inhibitors in BRCA1/2‐mutated cancers and immune checkpoint inhibitors in tumors with mismatch repair deficiency [<a href="#hon70131-bib-0055" class="usa-link" aria-describedby="hon70131-bib-0055">55</a>, <a href="#hon70131-bib-0056" class="usa-link" aria-describedby="hon70131-bib-0056">56</a>]. Several DDR protein addictions have emerged as potential targets for cancer therapy. BRCA1 mutations increase the risk of breast and ovarian cancers [<a href="#hon70131-bib-0057" class="usa-link" aria-describedby="hon70131-bib-0057">57</a>, <a href="#hon70131-bib-0058" class="usa-link" aria-describedby="hon70131-bib-0058">58</a>]. High expression of FANCA and FEN1 is associated with poor prognosis in pancreatic cancer [<a href="#hon70131-bib-0059" class="usa-link" aria-describedby="hon70131-bib-0059">59</a>]. PLOD1 upregulation promotes tumor growth and metastasis in lung and gastric cancers [<a href="#hon70131-bib-0060" class="usa-link" aria-describedby="hon70131-bib-0060">60</a>]. Upregulation of RAD51 indicates poor prognosis in breast, ovarian, and prostate cancers [<a href="#hon70131-bib-0061" class="usa-link" aria-describedby="hon70131-bib-0061">61</a>]. Synthetic lethality concepts are now also being harnessed in hematological malignancies like Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) animal models. A study demonstrated that aggressive CLL/SLL cells lacking ATM and P53 were vulnerable to PARP1 inhibition in mouse models [<a href="#hon70131-bib-0062" class="usa-link" aria-describedby="hon70131-bib-0062">62</a>]. DLBCL's complex genetic profile and aggressive nature present opportunities for exploiting synthetic lethal interactions. The disease is characterized by a high frequency of genetic alterations, including mutations in B‐cell receptor (BCR) pathway genes, MYD88, and CD79 B, sharing similarities with solid tumors where synthetic lethality therapies have shown promise. Future research could explore the application of SL approaches in DLBCL to develop personalized, targeted treatments that leverage the specific genetic vulnerabilities of this lymphoma subtype. Our research underscores the importance of assessing DDR alterations in the heterogeneous landscape of DLBCL to develop targeted synthetic lethality therapeutic strategies. However, limitations linked to toxicity should be investigated. The use of doxorubicin is limited by a well‐documented risk of cardiotoxicity, wich may manifest chronically or acutely [<a href="#hon70131-bib-0063" class="usa-link" aria-describedby="hon70131-bib-0063">63</a>]. The synergy between NU7441 and doxorubicin may be limited by the dose limitation of doxorubicin related to cardiotoxicity. Of interest, the combination of ATRi with cyclophosphamide did not demonstrated significant toxicity on normal cells in the primary samples of patients tested. Toxicity of ATR inhibitors have been investigated in murine models alone or in combination with ionizing radiotherapy [<a href="#hon70131-bib-0064" class="usa-link" aria-describedby="hon70131-bib-0064">64</a>]. Neutrophilia was observed with all ATRi tested even if ATR inhibitors did not exacerbate irradiation mediated toxicity [<a href="#hon70131-bib-0064" class="usa-link" aria-describedby="hon70131-bib-0064">64</a>]. Schmitz et al. reported that mutations in the Enhancer of Zeste Homolog 2 (EZH2) gene define a distinct subgroup with complex roles in DDR in DLBCL [<a href="#hon70131-bib-0006" class="usa-link" aria-describedby="hon70131-bib-0006">6</a>]. This subgroup demonstrates involvement in multiple aspects of DDR, including active participation in DNA repair processes and regulation of post‐DNA damage transcriptional programs [<a href="#hon70131-bib-0051" class="usa-link" aria-describedby="hon70131-bib-0051">51</a>]. More recently, we identified that iron homeostasis plays a major role in DLBCL pathophysiology [<a href="#hon70131-bib-0042" class="usa-link" aria-describedby="hon70131-bib-0042">42</a>]. Targeting iron homeostasis results in DDR, DNA double strand breaks, delayed progression of replication forks and synergistic activity with doxorubicin or targeted treatments in DLBCL cells [<a href="#hon70131-bib-0016" class="usa-link" aria-describedby="hon70131-bib-0016">16</a>]. This presents a promising avenue for developing more effective and tailored treatments for DLBCL patients.</p></section><section id="hon70131-sec-0150"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>S.O. and J.D. performed research and participated in the writing of the paper. L.A., L.D., M.A., E.G.P. and O.K.G. participated in the research. G.C. and C.H. participated in clinical data analysis and participated in the writing of the paper. C.S. participated in bioinformatic analyses. Y.L.L., A.C., O.E., P.P. and S.R. participated in the research and in the writing of the paper. J.M. and C.B. supervised the research and the writing of the paper.</p></section><section id="hon70131-sec-0170"><h2 class="pmc_sec_title">Ethics Statement</h2>
<p>Lymph node samples were collected after patients' written informed consent in accordance with the Declaration of Helsinki and institutional research board approval from Montpellier University Hospital (HEMODIAG_2020 cohort (ID‐RCB: 2011‐A00924‐37, <a href="https://clinicaltrials.gov/ct2/show/NCT02134574" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02134574</a>)).</p></section><section id="hon70131-sec-0180"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflicts of interest.</p></section><section id="hon70131-sec-0210"><h2 class="pmc_sec_title">Peer Review</h2>
<p>The peer review history for this article is available at <a href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.70131" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.70131</a>.</p></section><section id="sec19"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="hon70131-sup-0001"><div class="caption p"><p>
Supporting Information S1
</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s001.pdf</a><sup> (149.7KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="hon70131-sup-0002"><div class="caption p"><p>
Supporting Information S2
</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s005.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s005.pdf</a><sup> (18.8KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="hon70131-sup-0003"><div class="caption p"><p>
<strong>Figure S1:</strong> DDR genes are essential genes in DLBCL cells.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s010.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s010.pdf</a><sup> (108.9KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="hon70131-sup-0004"><div class="caption p"><p>
<strong>Figure S2:</strong> DNA repair scores are associated with drug response in DLBCL cell lines.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s004.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s004.pdf</a><sup> (90.1KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="hon70131-sup-0005"><div class="caption p"><p>
<strong>Figure S3:</strong> Effect of genotoxic drugs on apoptosis, cell cycle and DNA damage induction.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s002.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s002.pdf</a><sup> (112.8KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="hon70131-sup-0006"><div class="caption p"><p>
<strong>Figure S4:</strong> Effect of genotoxic drugs on apoptosis, cell cycle and DNA damage protein expression.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s003.jpg" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s003.jpg</a><sup> (718.3KB, jpg) </sup>
</div></div></section><section class="sm xbox font-sm" id="hon70131-sup-0007"><div class="caption p"><p>
<strong>Figure S5:</strong> Effect of drugs combination on apoptosis, cell cycle and DNA damage proteins expression.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s006.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s006.pdf</a><sup> (705.1KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="hon70131-sup-0008"><div class="caption p"><p>
<strong>Figure S6:</strong> Combinations of 4‐OH‐Cyclophosphamide with Chk1i and induces DNA replication stress.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s007.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s007.pdf</a><sup> (116.6KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="hon70131-sup-0009"><div class="caption p"><p>
<strong>Figure S7:</strong> Combination of DDR inhibitors with etoposide in DLBCL cells.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s009.jpg" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s009.jpg</a><sup> (761.1KB, jpg) </sup>
</div></div></section><section class="sm xbox font-sm" id="hon70131-sup-0010"><div class="caption p"><p>
<strong>Figure S8:</strong> Mononuclear cells from six patients with DLBCL were cultured for 4 days in the presence of CD40L.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s008.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s008.pdf</a><sup> (61KB, pdf) </sup>
</div></div></section></section><section id="hon70131-sec-0160" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>We acknowledge the imaging facility MRI, member of the France‐BioImaging national infrastructure supported by the French National Research Agency (ANR‐10‐INBS‐04, “Investments for the future”).</p></section><section id="notes1"><p>


Ovejero, Sara
, Devin Julie, Alibert Laura, et al. 2025. “Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High‐Risk Diffuse Large B Cell Lymphoma.”
Hematological Oncology: e70131. 10.1002/hon.70131.
</p>
<section id="fn-group1" class="fn-group"><div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="hon70131-note-0001"><p>
<strong>Funding:</strong> The J. Moreaux research group was supported by grants from INCA PLBIO22 PIC‐ASO (INCA_16734), ANR‐23‐CE15‐0016‐01 EPI‐B‐PLASMADIFF, SIRIC Montpellier Cancer (INCa‐DGOS‐INSERM‐ ITMO Cancer_ 18004), ARC foundation PGA EpiMM3D, Institut Carnot CALYM and a grant CALYM‐Janssen, FFRMG (AAP‐FFRMG‐2021), AAP ECOPHYTO—PELYCANO (This action is led by the Ministries for Agriculture and Food Sovereignty, for an Ecological Transition and Technical Cohesion, for Health and Prevention, and for Higher Education and Research, with the financial support of the French Office for Biodiversity, as part of the call for projects on the Ecophyto II + plan “Pgytosanitary products: from exposure to impacts on human health and ecosystems toward an integrated “one health” approach”, with the fees for diffuse pollution coming from the Ecophyto II + plan), AAP READYNOV, MSDAVENIR EpiMuM‐3D, Institut Universitaire de France and by the European Union (Project 101097094 — ELMUMY. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them. SO is supported by a grant from Fondation de France. SR is supported by grants from ARC Foundation, INCA PNP related to this project. We acknowledge the Canceropôle PACA and the CRISPR screen Labtech, label Aix‐Marseille platform for their support. Work in the PP laboratory is supported by Worldwide Cancer Research (Grant 23‐0344).</p></div>
<div class="fn p" id="hon70131-note-0002"><p>Sara Ovejero and Julie Devin contributed equally to this study.</p></div>
</div></section></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Jérôme Moreaux, Email: jerome.moreaux@igh.cnrs.fr.</p>
<p>Caroline Bret, Email: caroline.bret@igh.cnrs.fr.</p></section><section id="hon70131-sec-0200"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</p></section><section id="hon70131-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="hon70131-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="hon70131-bib-0001">
<span class="label">1.</span><cite>
Sehn L. H. and Salles G., “Diffuse Large B‐Cell Lymphoma. Reply,” New England Journal of Medicine
384, no. 23 (2021): 2262, 10.1056/NEJMc2105452.
</cite> [<a href="https://doi.org/10.1056/NEJMc2105452" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34107189/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma.%20Reply&amp;author=L.%20H.%20Sehn&amp;author=G.%20Salles&amp;volume=384&amp;issue=23&amp;publication_year=2021&amp;pages=2262&amp;pmid=34107189&amp;doi=10.1056/NEJMc2105452&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0002">
<span class="label">2.</span><cite>
Li S., Young K. H., and Medeiros L. J., “Diffuse Large B‐Cell Lymphoma,” Pathology
50, no. 1 (2018): 74–87, 10.1016/j.pathol.2017.09.006.
</cite> [<a href="https://doi.org/10.1016/j.pathol.2017.09.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29167021/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pathology&amp;title=Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=S.%20Li&amp;author=K.%20H.%20Young&amp;author=L.%20J.%20Medeiros&amp;volume=50&amp;issue=1&amp;publication_year=2018&amp;pages=74-87&amp;pmid=29167021&amp;doi=10.1016/j.pathol.2017.09.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0003">
<span class="label">3.</span><cite>
Staudt L. M. and Dave S., “The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling,” Advances in Immunology
87 (2005): 163–208, 10.1016/S0065-2776(05)87005-1.
</cite> [<a href="https://doi.org/10.1016/S0065-2776(05)87005-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1351148/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16102574/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Advances%20in%20Immunology&amp;title=The%20Biology%20of%20Human%20Lymphoid%20Malignancies%20Revealed%20by%20Gene%20Expression%20Profiling&amp;author=L.%20M.%20Staudt&amp;author=S.%20Dave&amp;volume=87&amp;publication_year=2005&amp;pages=163-208&amp;pmid=16102574&amp;doi=10.1016/S0065-2776(05)87005-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0004">
<span class="label">4.</span><cite>
Alizadeh A. A., Eisen M. B., Davis R. E., et al. “Distinct Types of Diffuse Large B‐Cell Lymphoma Identified by Gene Expression Profiling,” Nature
403, no. 6769 (2000): 503–511, 10.1038/35000501.
</cite> [<a href="https://doi.org/10.1038/35000501" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10676951/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Distinct%20Types%20of%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma%20Identified%20by%20Gene%20Expression%20Profiling&amp;author=A.%20A.%20Alizadeh&amp;author=M.%20B.%20Eisen&amp;author=R.%20E.%20Davis&amp;volume=403&amp;issue=6769&amp;publication_year=2000&amp;pages=503-511&amp;pmid=10676951&amp;doi=10.1038/35000501&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0005">
<span class="label">5.</span><cite>
Chapuy B., Stewart C., Dunford A. J., et al. “Molecular Subtypes of Diffuse Large B Cell Lymphoma are Associated With Distinct Pathogenic Mechanisms and Outcomes,” Nature Medicine
24, no. 5 (2018): 679–690, 10.1038/s41591-018-0016-8.</cite> [<a href="https://doi.org/10.1038/s41591-018-0016-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6613387/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29713087/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Medicine&amp;title=Molecular%20Subtypes%20of%20Diffuse%20Large%20B%20Cell%20Lymphoma%20are%20Associated%20With%20Distinct%20Pathogenic%20Mechanisms%20and%20Outcomes&amp;author=B.%20Chapuy&amp;author=C.%20Stewart&amp;author=A.%20J.%20Dunford&amp;volume=24&amp;issue=5&amp;publication_year=2018&amp;pages=679-690&amp;pmid=29713087&amp;doi=10.1038/s41591-018-0016-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0006">
<span class="label">6.</span><cite>
Schmitz R., Wright G. W., Huang D. W., et al. “Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma,” New England Journal of Medicine
378, no. 15 (2018): 1396–1407, 10.1056/NEJMoa1801445.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1801445" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6010183/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29641966/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Genetics%20and%20Pathogenesis%20of%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=R.%20Schmitz&amp;author=G.%20W.%20Wright&amp;author=D.%20W.%20Huang&amp;volume=378&amp;issue=15&amp;publication_year=2018&amp;pages=1396-1407&amp;pmid=29641966&amp;doi=10.1056/NEJMoa1801445&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0007">
<span class="label">7.</span><cite>
Wright G. W., Huang D. W., Phelan J. D., et al. “A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma With Therapeutic Implications,” Cancer Cell
37(4): 551‐568
e514 (2020), 10.1016/j.ccell.2020.03.015.
</cite> [<a href="https://doi.org/10.1016/j.ccell.2020.03.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8459709/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32289277/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=A%20Probabilistic%20Classification%20Tool%20for%20Genetic%20Subtypes%20of%20Diffuse%20Large%20B%20Cell%20Lymphoma%20With%20Therapeutic%20Implications&amp;author=G.%20W.%20Wright&amp;author=D.%20W.%20Huang&amp;author=J.%20D.%20Phelan&amp;volume=37&amp;issue=4&amp;publication_year=2020&amp;pages=551-568&amp;pmid=32289277&amp;doi=10.1016/j.ccell.2020.03.015&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0008">
<span class="label">8.</span><cite>
Kotlov N., Bagaev A., Revuelta M. V., et al. “Clinical and Biological Subtypes of B‐Cell Lymphoma Revealed by Microenvironmental Signatures,” Cancer Discovery
11, no. 6 (2021): 1468–1489, 10.1158/2159-8290.CD-20-0839.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-20-0839" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8178179/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33541860/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discovery&amp;title=Clinical%20and%20Biological%20Subtypes%20of%20B%E2%80%90Cell%20Lymphoma%20Revealed%20by%20Microenvironmental%20Signatures&amp;author=N.%20Kotlov&amp;author=A.%20Bagaev&amp;author=M.%20V.%20Revuelta&amp;volume=11&amp;issue=6&amp;publication_year=2021&amp;pages=1468-1489&amp;pmid=33541860&amp;doi=10.1158/2159-8290.CD-20-0839&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0009">
<span class="label">9.</span><cite>
Groehler A. T., Villalta P. W., Campbell C., and Tretyakova N., “Covalent DNA–Protein Cross‐Linking by Phosphoramide Mustard and Nornitrogen Mustard in Human Cells,” Chemical Research in Toxicology
29, no. 2 (2016): 190–202, 10.1021/acs.chemrestox.5b00430.
</cite> [<a href="https://doi.org/10.1021/acs.chemrestox.5b00430" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4755881/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26692166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chemical%20Research%20in%20Toxicology&amp;title=Covalent%20DNA%E2%80%93Protein%20Cross%E2%80%90Linking%20by%20Phosphoramide%20Mustard%20and%20Nornitrogen%20Mustard%20in%20Human%20Cells&amp;author=A.%20T.%20Groehler&amp;author=P.%20W.%20Villalta&amp;author=C.%20Campbell&amp;author=N.%20Tretyakova&amp;volume=29&amp;issue=2&amp;publication_year=2016&amp;pages=190-202&amp;pmid=26692166&amp;doi=10.1021/acs.chemrestox.5b00430&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0010">
<span class="label">10.</span><cite>
Rivankar S., “An Overview of Doxorubicin Formulations in Cancer Therapy,” Journal of Cancer Research and Therapeutics
10, no. 4 (2014): 853–858, 10.4103/0973-1482.139267.
</cite> [<a href="https://doi.org/10.4103/0973-1482.139267" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25579518/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Cancer%20Research%20and%20Therapeutics&amp;title=An%20Overview%20of%20Doxorubicin%20Formulations%20in%20Cancer%20Therapy&amp;author=S.%20Rivankar&amp;volume=10&amp;issue=4&amp;publication_year=2014&amp;pages=853-858&amp;pmid=25579518&amp;doi=10.4103/0973-1482.139267&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0011">
<span class="label">11.</span><cite>
Martino E., Casamassima G., Castiglione S., et al. “Vinca Alkaloids and Analogues as Anti‐Cancer Agents: Looking Back, Peering Ahead,” Bioorganic &amp; Medicinal Chemistry Letters
28, no. 17 (2018): 2816–2826, 10.1016/j.bmcl.2018.06.044.
</cite> [<a href="https://doi.org/10.1016/j.bmcl.2018.06.044" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30122223/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorganic%20&amp;%20Medicinal%20Chemistry%20Letters&amp;title=Vinca%20Alkaloids%20and%20Analogues%20as%20Anti%E2%80%90Cancer%20Agents:%20Looking%20Back,%20Peering%20Ahead&amp;author=E.%20Martino&amp;author=G.%20Casamassima&amp;author=S.%20Castiglione&amp;volume=28&amp;issue=17&amp;publication_year=2018&amp;pages=2816-2826&amp;pmid=30122223&amp;doi=10.1016/j.bmcl.2018.06.044&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0012">
<span class="label">12.</span><cite>
Moccia A. A., Hitz F., Hoskins P., et al. “Gemcitabine, Dexamethasone, and Cisplatin (GDP) is an Effective and Well‐Tolerated Salvage Therapy for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma and Hodgkin Lymphoma,” Leukemia and Lymphoma
58, no. 2 (2017): 324–332, 10.1080/10428194.2016.1193852.
</cite> [<a href="https://doi.org/10.1080/10428194.2016.1193852" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27347845/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia%20and%20Lymphoma&amp;title=Gemcitabine,%20Dexamethasone,%20and%20Cisplatin%20(GDP)%20is%20an%20Effective%20and%20Well%E2%80%90Tolerated%20Salvage%20Therapy%20for%20Relapsed/Refractory%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma%20and%20Hodgkin%20Lymphoma&amp;author=A.%20A.%20Moccia&amp;author=F.%20Hitz&amp;author=P.%20Hoskins&amp;volume=58&amp;issue=2&amp;publication_year=2017&amp;pages=324-332&amp;pmid=27347845&amp;doi=10.1080/10428194.2016.1193852&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0013">
<span class="label">13.</span><cite>
Herrera A. F., Chen L., Crombie J. L., et al. “Polatuzumab Vedotin Combined With R‐ICE (PolaR‐ICE) as Second‐Line Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma,” Blood
140, no. 1 (2022): 1065–1067, 10.1182/blood-2022-165699.</cite> [<a href="https://doi.org/10.1182/blood-2022-165699" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Polatuzumab%20Vedotin%20Combined%20With%20R%E2%80%90ICE%20(PolaR%E2%80%90ICE)%20as%20Second%E2%80%90Line%20Therapy%20in%20Relapsed/Refractory%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=A.%20F.%20Herrera&amp;author=L.%20Chen&amp;author=J.%20L.%20Crombie&amp;volume=140&amp;issue=1&amp;publication_year=2022&amp;pages=1065-1067&amp;doi=10.1182/blood-2022-165699&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0014">
<span class="label">14.</span><cite>
Aussedat G., Maucort‐Boulch D., Rey P., et al. “Rituximab in Combination With Adapted‐Dose of Ifosfamide and Etoposide as Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B‐Cell Lymphoma Patients Non‐Candidate for High Dose Therapy: A Retrospective Study,” Leukemia and Lymphoma
63, no. 3 (2022): 599–607, 10.1080/10428194.2021.1998483.
</cite> [<a href="https://doi.org/10.1080/10428194.2021.1998483" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34720034/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia%20and%20Lymphoma&amp;title=Rituximab%20in%20Combination%20With%20Adapted%E2%80%90Dose%20of%20Ifosfamide%20and%20Etoposide%20as%20Salvage%20Treatment%20in%20Elderly%20Refractory/Relapsed%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma%20Patients%20Non%E2%80%90Candidate%20for%20High%20Dose%20Therapy:%20A%20Retrospective%20Study&amp;author=G.%20Aussedat&amp;author=D.%20Maucort%E2%80%90Boulch&amp;author=P.%20Rey&amp;volume=63&amp;issue=3&amp;publication_year=2022&amp;pages=599-607&amp;pmid=34720034&amp;doi=10.1080/10428194.2021.1998483&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0015">
<span class="label">15.</span><cite>
Joel S. P., Shah R., Clark P. I., and Slevin M. L., “Predicting Etoposide Toxicity: Relationship to Organ Function and Protein Binding,” Journal of Clinical Oncology
14, no. 1 (1996): 257–267, 10.1200/JCO.1996.14.1.257.
</cite> [<a href="https://doi.org/10.1200/JCO.1996.14.1.257" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8558207/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Predicting%20Etoposide%20Toxicity:%20Relationship%20to%20Organ%20Function%20and%20Protein%20Binding&amp;author=S.%20P.%20Joel&amp;author=R.%20Shah&amp;author=P.%20I.%20Clark&amp;author=M.%20L.%20Slevin&amp;volume=14&amp;issue=1&amp;publication_year=1996&amp;pages=257-267&amp;pmid=8558207&amp;doi=10.1200/JCO.1996.14.1.257&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0016">
<span class="label">16.</span><cite>
Bret C., Klein B., Cartron G., et al. “DNA Repair in Diffuse Large B‐Cell Lymphoma: A Molecular Portrait,” British Journal of Haematology
169, no. 2 (2015): 296–299, 10.1111/bjh.13206.
</cite> [<a href="https://doi.org/10.1111/bjh.13206" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25369781/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Haematology&amp;title=DNA%20Repair%20in%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma:%20A%20Molecular%20Portrait&amp;author=C.%20Bret&amp;author=B.%20Klein&amp;author=G.%20Cartron&amp;volume=169&amp;issue=2&amp;publication_year=2015&amp;pages=296-299&amp;pmid=25369781&amp;doi=10.1111/bjh.13206&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0017">
<span class="label">17.</span><cite>
Halazonetis T. D., Gorgoulis V. G., and Bartek J., “An Oncogene‐Induced DNA Damage Model for Cancer Development,” Science
319, no. 5868 (2008): 1352–1355, 10.1126/science.1140735.
</cite> [<a href="https://doi.org/10.1126/science.1140735" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18323444/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=An%20Oncogene%E2%80%90Induced%20DNA%20Damage%20Model%20for%20Cancer%20Development&amp;author=T.%20D.%20Halazonetis&amp;author=V.%20G.%20Gorgoulis&amp;author=J.%20Bartek&amp;volume=319&amp;issue=5868&amp;publication_year=2008&amp;pages=1352-1355&amp;pmid=18323444&amp;doi=10.1126/science.1140735&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0018">
<span class="label">18.</span><cite>
Negrini S., Gorgoulis V. G., and Halazonetis T. D., “Genomic Instability — An Evolving Hallmark of Cancer,” Nature Reviews Molecular Cell Biology
11, no. 3 (2010): 220–228, 10.1038/nrm2858.
</cite> [<a href="https://doi.org/10.1038/nrm2858" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20177397/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Molecular%20Cell%20Biology&amp;title=Genomic%20Instability%20%E2%80%94%20An%20Evolving%20Hallmark%20of%20Cancer&amp;author=S.%20Negrini&amp;author=V.%20G.%20Gorgoulis&amp;author=T.%20D.%20Halazonetis&amp;volume=11&amp;issue=3&amp;publication_year=2010&amp;pages=220-228&amp;pmid=20177397&amp;doi=10.1038/nrm2858&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0019">
<span class="label">19.</span><cite>
Macheret M. and Halazonetis T. D., “DNA Replication Stress as a Hallmark of Cancer,” Annual Review of Pathology: Mechanisms of Disease
10, no. 1 (2015): 425–448, 10.1146/annurev-pathol-012414-040424.</cite> [<a href="https://doi.org/10.1146/annurev-pathol-012414-040424" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25621662/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annual%20Review%20of%20Pathology:%20Mechanisms%20of%20Disease&amp;title=DNA%20Replication%20Stress%20as%20a%20Hallmark%20of%20Cancer&amp;author=M.%20Macheret&amp;author=T.%20D.%20Halazonetis&amp;volume=10&amp;issue=1&amp;publication_year=2015&amp;pages=425-448&amp;pmid=25621662&amp;doi=10.1146/annurev-pathol-012414-040424&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0020">
<span class="label">20.</span><cite>
Shaheen M., Allen C., Nickoloff J. A., and Hromas R., “Synthetic Lethality: Exploiting the Addiction of Cancer to DNA Repair,” Blood
117, no. 23 (2011): 6074–6082, 10.1182/blood-2011-01-313734.
</cite> [<a href="https://doi.org/10.1182/blood-2011-01-313734" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21441464/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Synthetic%20Lethality:%20Exploiting%20the%20Addiction%20of%20Cancer%20to%20DNA%20Repair&amp;author=M.%20Shaheen&amp;author=C.%20Allen&amp;author=J.%20A.%20Nickoloff&amp;author=R.%20Hromas&amp;volume=117&amp;issue=23&amp;publication_year=2011&amp;pages=6074-6082&amp;pmid=21441464&amp;doi=10.1182/blood-2011-01-313734&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0021">
<span class="label">21.</span><cite>
O'Connor M. J., “Targeting the DNA Damage Response in Cancer,” Molecular Cell
60, no. 4 (2015): 547–560, 10.1016/j.molcel.2015.10.040.
</cite> [<a href="https://doi.org/10.1016/j.molcel.2015.10.040" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26590714/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cell&amp;title=Targeting%20the%20DNA%20Damage%20Response%20in%20Cancer&amp;author=M.%20J.%20O'Connor&amp;volume=60&amp;issue=4&amp;publication_year=2015&amp;pages=547-560&amp;pmid=26590714&amp;doi=10.1016/j.molcel.2015.10.040&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0022">
<span class="label">22.</span><cite>
Bhattacharjee S. and Nandi S., “Synthetic Lethality in DNA Repair Network: A Novel Avenue in Targeted Cancer Therapy and Combination Therapeutics,” IUBMB Life
69, no. 12 (2017): 929–937, 10.1002/iub.1696.
</cite> [<a href="https://doi.org/10.1002/iub.1696" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29171189/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=IUBMB%20Life&amp;title=Synthetic%20Lethality%20in%20DNA%20Repair%C2%A0Network:%20A%20Novel%20Avenue%20in%20Targeted%20Cancer%20Therapy%20and%20Combination%20Therapeutics&amp;author=S.%20Bhattacharjee&amp;author=S.%20Nandi&amp;volume=69&amp;issue=12&amp;publication_year=2017&amp;pages=929-937&amp;pmid=29171189&amp;doi=10.1002/iub.1696&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0023">
<span class="label">23.</span><cite>
Phelan J. D., Young R. M., Webster D. E., et al. “A Multiprotein Supercomplex Controlling Oncogenic Signalling in Lymphoma,” Nature
560, no. 7718 (2018): 387–391, 10.1038/s41586-018-0290-0.
</cite> [<a href="https://doi.org/10.1038/s41586-018-0290-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6201842/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29925955/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=A%20Multiprotein%20Supercomplex%20Controlling%20Oncogenic%20Signalling%20in%20Lymphoma&amp;author=J.%20D.%20Phelan&amp;author=R.%20M.%20Young&amp;author=D.%20E.%20Webster&amp;volume=560&amp;issue=7718&amp;publication_year=2018&amp;pages=387-391&amp;pmid=29925955&amp;doi=10.1038/s41586-018-0290-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0024">
<span class="label">24.</span><cite>
Qiu Z., Oleinick N. L., and Zhang J., “ATR/CHK1 Inhibitors and Cancer Therapy,” Radiotherapy &amp; Oncology
126, no. 3 (2018): 450–464, 10.1016/j.radonc.2017.09.043.
</cite> [<a href="https://doi.org/10.1016/j.radonc.2017.09.043" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5856582/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29054375/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiotherapy%20&amp;%20Oncology&amp;title=ATR/CHK1%20Inhibitors%20and%20Cancer%20Therapy&amp;author=Z.%20Qiu&amp;author=N.%20L.%20Oleinick&amp;author=J.%20Zhang&amp;volume=126&amp;issue=3&amp;publication_year=2018&amp;pages=450-464&amp;pmid=29054375&amp;doi=10.1016/j.radonc.2017.09.043&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0025">
<span class="label">25.</span><cite>
Ma J., Liu W., Li J., et al. “Azenosertib is a Potent and Selective WEE1 Kinase Inhibitor With Broad Antitumor Activity Across a Range of Solid Tumors,” Molecular Cancer Therapeutics
24, no. 8 (2025): 1171–1185, 10.1158/1535-7163.MCT-24-1194.
</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-24-1194" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12314526/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40231599/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cancer%20Therapeutics&amp;title=Azenosertib%20is%20a%20Potent%20and%20Selective%20WEE1%20Kinase%20Inhibitor%20With%20Broad%20Antitumor%20Activity%20Across%20a%20Range%20of%20Solid%20Tumors&amp;author=J.%20Ma&amp;author=W.%20Liu&amp;author=J.%20Li&amp;volume=24&amp;issue=8&amp;publication_year=2025&amp;pages=1171-1185&amp;pmid=40231599&amp;doi=10.1158/1535-7163.MCT-24-1194&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0026">
<span class="label">26.</span><cite>
Yap T. A., Miller C., Stenehjem D., Brown E. J., Carleton M., and Mirza N. Q., “Abstract CT195: First‐In‐Human Phase 1 Study of WEE1 Inhibitor APR‐1051 in Patients With Advanced Solid Tumors Harboring Cancer‐Associated Gene Alterations,” Cancer Research
84, no. 7 (2024): CT195, 10.1158/1538-7445.Am2024-ct195.</cite> [<a href="https://doi.org/10.1158/1538-7445.Am2024-ct195" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Research&amp;title=Abstract%20CT195:%20First%E2%80%90In%E2%80%90Human%20Phase%201%20Study%20of%20WEE1%20Inhibitor%20APR%E2%80%901051%20in%20Patients%20With%20Advanced%20Solid%20Tumors%20Harboring%20Cancer%E2%80%90Associated%20Gene%20Alterations&amp;author=T.%20A.%20Yap&amp;author=C.%20Miller&amp;author=D.%20Stenehjem&amp;author=E.%20J.%20Brown&amp;author=M.%20Carleton&amp;volume=84&amp;issue=7&amp;publication_year=2024&amp;pages=CT195&amp;doi=10.1158/1538-7445.Am2024-ct195&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0027">
<span class="label">27.</span><cite>
Yap T. A., Fontana E., Lee E. K., et al. “Camonsertib in DNA Damage Response‐Deficient Advanced Solid Tumors: Phase 1 Trial Results,” Nature Medicine
29, no. 6 (2023): 1400–1411, 10.1038/s41591-023-02399-0.</cite> [<a href="https://doi.org/10.1038/s41591-023-02399-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10287555/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37277454/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Medicine&amp;title=Camonsertib%20in%20DNA%20Damage%20Response%E2%80%90Deficient%20Advanced%20Solid%20Tumors:%20Phase%201%20Trial%20Results&amp;author=T.%20A.%20Yap&amp;author=E.%20Fontana&amp;author=E.%20K.%20Lee&amp;volume=29&amp;issue=6&amp;publication_year=2023&amp;pages=1400-1411&amp;pmid=37277454&amp;doi=10.1038/s41591-023-02399-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0028">
<span class="label">28.</span><cite>
Yap T. A., Tolcher A. W., Plummer R., et al. “First‐In‐Human Study of the Ataxia Telangiectasia and Rad3‐Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients With Solid Tumors,” Clinical Cancer Research
30, no. 10 (2024): 2057–2067, 10.1158/1078-0432.CCR-23-2409.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-23-2409" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11094421/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38407317/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Cancer%20Research&amp;title=First%E2%80%90In%E2%80%90Human%20Study%20of%20the%20Ataxia%20Telangiectasia%20and%20Rad3%E2%80%90Related%20(ATR)%20Inhibitor%20Tuvusertib%20(M1774)%20as%20Monotherapy%20in%20Patients%20With%20Solid%20Tumors&amp;author=T.%20A.%20Yap&amp;author=A.%20W.%20Tolcher&amp;author=R.%20Plummer&amp;volume=30&amp;issue=10&amp;publication_year=2024&amp;pages=2057-2067&amp;pmid=38407317&amp;doi=10.1158/1078-0432.CCR-23-2409&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0029">
<span class="label">29.</span><cite>
McGowan C. H. and Russell P., “Cell Cycle Regulation of Human WEE1,” EMBO Journal
14, no. 10 (1995): 2166–2175, 10.1002/j.1460-2075.1995.tb07210.x.
</cite> [<a href="https://doi.org/10.1002/j.1460-2075.1995.tb07210.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC398322/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7774574/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=EMBO%20Journal&amp;title=Cell%20Cycle%20Regulation%20of%20Human%20WEE1&amp;author=C.%20H.%20McGowan&amp;author=P.%20Russell&amp;volume=14&amp;issue=10&amp;publication_year=1995&amp;pages=2166-2175&amp;pmid=7774574&amp;doi=10.1002/j.1460-2075.1995.tb07210.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0030">
<span class="label">30.</span><cite>
Elbaek C. R., Petrosius V., and Sorensen C. S., “WEE1 Kinase Limits CDK Activities to Safeguard DNA Replication and Mitotic Entry,” Mutation Research (2020): 819‐820
111694, 10.1016/j.mrfmmm.2020.111694.</cite> [<a href="https://doi.org/10.1016/j.mrfmmm.2020.111694" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32120135/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mutation%20Research&amp;title=WEE1%20Kinase%20Limits%20CDK%20Activities%20to%20Safeguard%20DNA%20Replication%20and%20Mitotic%20Entry&amp;author=C.%20R.%20Elbaek&amp;author=V.%20Petrosius&amp;author=C.%20S.%20Sorensen&amp;publication_year=2020&amp;pages=819-820&amp;pmid=32120135&amp;doi=10.1016/j.mrfmmm.2020.111694&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0031">
<span class="label">31.</span><cite>
Laurini E., Marson D., Fermeglia A., Aulic S., Fermeglia M., and Pricl S., “Role of Rad51 and DNA Repair in Cancer: A Molecular Perspective,” Pharmacology &amp; Therapeutics
208 (2020): 107492, 10.1016/j.pharmthera.2020.107492.
</cite> [<a href="https://doi.org/10.1016/j.pharmthera.2020.107492" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32001312/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacology%20&amp;%20Therapeutics&amp;title=Role%20of%20Rad51%20and%20DNA%20Repair%20in%20Cancer:%20A%20Molecular%20Perspective&amp;author=E.%20Laurini&amp;author=D.%20Marson&amp;author=A.%20Fermeglia&amp;author=S.%20Aulic&amp;author=M.%20Fermeglia&amp;volume=208&amp;publication_year=2020&amp;pages=107492&amp;pmid=32001312&amp;doi=10.1016/j.pharmthera.2020.107492&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0032">
<span class="label">32.</span><cite>
Shkundina I. S., Gall A. A., Dick A., Cocklin S., and Mazin A. V., “New RAD51 Inhibitors to Target Homologous Recombination in Human Cells,” Genes
12, no. 6 (2021): 920, 10.3390/genes12060920.
</cite> [<a href="https://doi.org/10.3390/genes12060920" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8235719/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34208492/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genes&amp;title=New%20RAD51%20Inhibitors%20to%20Target%20Homologous%20Recombination%20in%20Human%20Cells&amp;author=I.%20S.%20Shkundina&amp;author=A.%20A.%20Gall&amp;author=A.%20Dick&amp;author=S.%20Cocklin&amp;author=A.%20V.%20Mazin&amp;volume=12&amp;issue=6&amp;publication_year=2021&amp;pages=920&amp;pmid=34208492&amp;doi=10.3390/genes12060920&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0033">
<span class="label">33.</span><cite>
de Jong M. R. W., Langendonk M., Reitsma B., et al. “WEE1 Inhibition Synergizes With CHOP Chemotherapy and Radiation Therapy Through Induction of Premature Mitotic Entry and DNA Damage in Diffuse Large B‐Cell Lymphoma,” Therapeutic Advances in Hematology
11 (2020): 2040620719898373, 10.1177/2040620719898373.
</cite> [<a href="https://doi.org/10.1177/2040620719898373" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6971956/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32010435/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therapeutic%20Advances%20in%20Hematology&amp;title=WEE1%20Inhibition%20Synergizes%20With%20CHOP%20Chemotherapy%20and%20Radiation%20Therapy%20Through%20Induction%20of%20Premature%20Mitotic%20Entry%20and%20DNA%20Damage%20in%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=M.%20R.%20W.%20de%20Jong&amp;author=M.%20Langendonk&amp;author=B.%20Reitsma&amp;volume=11&amp;publication_year=2020&amp;pages=2040620719898373&amp;pmid=32010435&amp;doi=10.1177/2040620719898373&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0034">
<span class="label">34.</span><cite>
Chila R., Basana A., Lupi M., et al. “Combined Inhibition of Chk1 and Wee1 as a New Therapeutic Strategy for Mantle Cell Lymphoma,” Oncotarget
6, no. 5 (2015): 3394–3408, 10.18632/oncotarget.2583.
</cite> [<a href="https://doi.org/10.18632/oncotarget.2583" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4413661/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25428911/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Combined%20Inhibition%20of%20Chk1%20and%20Wee1%20as%20a%20New%20Therapeutic%20Strategy%20for%20Mantle%20Cell%20Lymphoma&amp;author=R.%20Chila&amp;author=A.%20Basana&amp;author=M.%20Lupi&amp;volume=6&amp;issue=5&amp;publication_year=2015&amp;pages=3394-3408&amp;pmid=25428911&amp;doi=10.18632/oncotarget.2583&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0035">
<span class="label">35.</span><cite>
Restelli V., Vagni M., Arribas A. J., Bertoni F., Damia G., and Carrassa L., “Inhibition of CHK1 and WEE1 as a New Therapeutic Approach in Diffuse Large B Cell Lymphomas With MYC Deregulation,” British Journal of Haematology
181, no. 1 (2018): 129–133, 10.1111/bjh.14506.
</cite> [<a href="https://doi.org/10.1111/bjh.14506" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28025833/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Haematology&amp;title=Inhibition%20of%20CHK1%20and%20WEE1%20as%20a%20New%20Therapeutic%20Approach%20in%20Diffuse%20Large%20B%20Cell%20Lymphomas%20With%20MYC%20Deregulation&amp;author=V.%20Restelli&amp;author=M.%20Vagni&amp;author=A.%20J.%20Arribas&amp;author=F.%20Bertoni&amp;author=G.%20Damia&amp;volume=181&amp;issue=1&amp;publication_year=2018&amp;pages=129-133&amp;pmid=28025833&amp;doi=10.1111/bjh.14506&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0036">
<span class="label">36.</span><cite>
Young L. A., O'Connor L. O., de Renty C., et al. “Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.” Cancer Research
79 (2019): 3762–3775, 10.1158/0008-5472.CAN-18-2480.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-18-2480" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31123088/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Research&amp;title=Differential%20Activity%20of%20ATR%20and%20WEE1%20Inhibitors%20in%20a%20Highly%20Sensitive%20Subpopulation%20of%20DLBCL%20Linked%20to%20Replication%20Stress&amp;author=L.%20A.%20Young&amp;author=L.%20O.%20O'Connor&amp;author=C.%20de%20Renty&amp;volume=79&amp;publication_year=2019&amp;pages=3762-3775&amp;pmid=31123088&amp;doi=10.1158/0008-5472.CAN-18-2480&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0037">
<span class="label">37.</span><cite>
Sartori G., Tarantelli C., Spriano F., et al. “The ATR Inhibitor Elimusertib Exhibits Anti‐Lymphoma Activity and Synergizes With the PI3K Inhibitor Copanlisib,” British Journal of Haematology
204, no. 1 (2024): 191–205, 10.1111/bjh.19218.
</cite> [<a href="https://doi.org/10.1111/bjh.19218" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38011941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Haematology&amp;title=The%20ATR%20Inhibitor%20Elimusertib%20Exhibits%20Anti%E2%80%90Lymphoma%20Activity%20and%20Synergizes%20With%20the%20PI3K%20Inhibitor%20Copanlisib&amp;author=G.%20Sartori&amp;author=C.%20Tarantelli&amp;author=F.%20Spriano&amp;volume=204&amp;issue=1&amp;publication_year=2024&amp;pages=191-205&amp;pmid=38011941&amp;doi=10.1111/bjh.19218&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0038">
<span class="label">38.</span><cite>
Yap T. A., Tan D. S. P., Terbuch A., et al. “First‐In‐Human Trial of the Oral Ataxia Telangiectasia and RAD3‐Related (ATR) Inhibitor BAY 1895344 in Patients With Advanced Solid Tumors,” Cancer Discovery
11, no. 1 (2021): 80–91, 10.1158/2159-8290.CD-20-0868.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-20-0868" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9554790/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32988960/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discovery&amp;title=First%E2%80%90In%E2%80%90Human%20Trial%20of%20the%20Oral%20Ataxia%20Telangiectasia%20and%20RAD3%E2%80%90Related%20(ATR)%20Inhibitor%20BAY%201895344%20in%20Patients%20With%20Advanced%20Solid%20Tumors&amp;author=T.%20A.%20Yap&amp;author=D.%20S.%20P.%20Tan&amp;author=A.%20Terbuch&amp;volume=11&amp;issue=1&amp;publication_year=2021&amp;pages=80-91&amp;pmid=32988960&amp;doi=10.1158/2159-8290.CD-20-0868&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0039">
<span class="label">39.</span><cite>
Chen Y., Yang W., Zheng J., Bernards R., and Jin H., “Drug–Drug Synthetic Lethality to Combat Cancer: From Bench to Bedside,” Clinical and Translational Medicine
13, no. 5 (2023): e1269, 10.1002/ctm2.1269.
</cite> [<a href="https://doi.org/10.1002/ctm2.1269" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10204170/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37218919/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20and%20Translational%20Medicine&amp;title=Drug%E2%80%93Drug%20Synthetic%20Lethality%20to%20Combat%20Cancer:%20From%20Bench%20to%20Bedside&amp;author=Y.%20Chen&amp;author=W.%20Yang&amp;author=J.%20Zheng&amp;author=R.%20Bernards&amp;author=H.%20Jin&amp;volume=13&amp;issue=5&amp;publication_year=2023&amp;pages=e1269&amp;pmid=37218919&amp;doi=10.1002/ctm2.1269&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0040">
<span class="label">40.</span><cite>
Jin H., Wang L., and Bernards R., “Rational Combinations of Targeted Cancer Therapies: Background, Advances and Challenges,” Nature Reviews Drug Discovery
22, no. 3 (2023): 213–234, 10.1038/s41573-022-00615-z.
</cite> [<a href="https://doi.org/10.1038/s41573-022-00615-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36509911/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Drug%20Discovery&amp;title=Rational%20Combinations%20of%20Targeted%20Cancer%20Therapies:%20Background,%20Advances%20and%20Challenges&amp;author=H.%20Jin&amp;author=L.%20Wang&amp;author=R.%20Bernards&amp;volume=22&amp;issue=3&amp;publication_year=2023&amp;pages=213-234&amp;pmid=36509911&amp;doi=10.1038/s41573-022-00615-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0041">
<span class="label">41.</span><cite>
Tsherniak A., Vazquez F., Montgomery P. G., et al. “Defining a Cancer Dependency Map.” Cell
170(3): 564‐576
e516 (2017), 10.1016/j.cell.2017.06.010.
</cite> [<a href="https://doi.org/10.1016/j.cell.2017.06.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5667678/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28753430/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Defining%20a%20Cancer%20Dependency%20Map&amp;author=A.%20Tsherniak&amp;author=F.%20Vazquez&amp;author=P.%20G.%20Montgomery&amp;volume=170&amp;issue=3&amp;publication_year=2017&amp;pages=564-576&amp;pmid=28753430&amp;doi=10.1016/j.cell.2017.06.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0042">
<span class="label">42.</span><cite>
Devin J., Caneque T., Lin Y. L., et al. “Targeting Cellular Iron Homeostasis With Ironomycin in Diffuse Large B‐Cell Lymphoma,” Cancer Research
82, no. 6 (2022): 998–1012, 10.1158/0008-5472.CAN-21-0218.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-21-0218" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9359736/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35078814/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Research&amp;title=Targeting%20Cellular%20Iron%20Homeostasis%20With%20Ironomycin%20in%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=J.%20Devin&amp;author=T.%20Caneque&amp;author=Y.%20L.%20Lin&amp;volume=82&amp;issue=6&amp;publication_year=2022&amp;pages=998-1012&amp;pmid=35078814&amp;doi=10.1158/0008-5472.CAN-21-0218&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0043">
<span class="label">43.</span><cite>
Bruyer A., Dutrieux L., de Boussac H., et al. “Combined Inhibition of Wee1 and Chk1 as a Therapeutic Strategy in Multiple Myeloma,” Frontiers in Oncology
13 (2023): 1271847, 10.3389/fonc.2023.1271847.
</cite> [<a href="https://doi.org/10.3389/fonc.2023.1271847" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10730928/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38125947/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Oncology&amp;title=Combined%20Inhibition%20of%20Wee1%20and%20Chk1%20as%20a%20Therapeutic%20Strategy%20in%20Multiple%20Myeloma&amp;author=A.%20Bruyer&amp;author=L.%20Dutrieux&amp;author=H.%20de%20Boussac&amp;volume=13&amp;publication_year=2023&amp;pages=1271847&amp;pmid=38125947&amp;doi=10.3389/fonc.2023.1271847&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0044">
<span class="label">44.</span><cite>
Chou T. C. and Talalay P., “Quantitative Analysis of Dose‐Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors,” Advances in Enzyme Regulation
22 (1984): 27–55, 10.1016/0065-2571(84)90007-4.
</cite> [<a href="https://doi.org/10.1016/0065-2571(84)90007-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/6382953/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Advances%20in%20Enzyme%20Regulation&amp;title=Quantitative%20Analysis%20of%20Dose%E2%80%90Effect%20Relationships:%20The%20Combined%20Effects%20of%20Multiple%20Drugs%20or%20Enzyme%20Inhibitors&amp;author=T.%20C.%20Chou&amp;author=P.%20Talalay&amp;volume=22&amp;publication_year=1984&amp;pages=27-55&amp;pmid=6382953&amp;doi=10.1016/0065-2571(84)90007-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0045">
<span class="label">45.</span><cite>
de Boussac H., Bruyer A., Jourdan M., et al. “Kinome Expression Profiling to Target New Therapeutic Avenues in Multiple Myeloma,” Haematologica
105, no. 3 (2020): 784–795, 10.3324/haematol.2018.208306.
</cite> [<a href="https://doi.org/10.3324/haematol.2018.208306" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7049359/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31289205/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=Kinome%20Expression%20Profiling%20to%20Target%20New%20Therapeutic%20Avenues%20in%20Multiple%20Myeloma&amp;author=H.%20de%20Boussac&amp;author=A.%20Bruyer&amp;author=M.%20Jourdan&amp;volume=105&amp;issue=3&amp;publication_year=2020&amp;pages=784-795&amp;pmid=31289205&amp;doi=10.3324/haematol.2018.208306&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0046">
<span class="label">46.</span><cite>
Bryant C., Scriven K., and Massey A. J., “Inhibition of the Checkpoint Kinase Chk1 Induces DNA Damage and Cell Death in Human Leukemia and Lymphoma Cells,” Molecular Cancer
13, no. 1 (2014): 147, 10.1186/1476-4598-13-147.
</cite> [<a href="https://doi.org/10.1186/1476-4598-13-147" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4082411/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24913641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cancer&amp;title=Inhibition%20of%20the%20Checkpoint%20Kinase%20Chk1%20Induces%20DNA%20Damage%20and%20Cell%20Death%20in%20Human%20Leukemia%20and%20Lymphoma%20Cells&amp;author=C.%20Bryant&amp;author=K.%20Scriven&amp;author=A.%20J.%20Massey&amp;volume=13&amp;issue=1&amp;publication_year=2014&amp;pages=147&amp;pmid=24913641&amp;doi=10.1186/1476-4598-13-147&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0047">
<span class="label">47.</span><cite>
Ferrão P. T., Cullinane C., Raleigh J., et al. “Abstract 2499: Single Agent Activity of Checkpoint Kinase Inhibitor PF‐477736, in a MYC‐Driven Lymphoma Model,” Cancer Research
70, no. 8 (2010): 2499, 10.1158/1538-7445.Am10-2499.</cite> [<a href="https://doi.org/10.1158/1538-7445.Am10-2499" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Research&amp;title=Abstract%202499:%20Single%20Agent%20Activity%20of%20Checkpoint%20Kinase%20Inhibitor%20PF%E2%80%90477736,%20in%20a%20MYC%E2%80%90Driven%20Lymphoma%20Model&amp;author=P.%20T.%20Ferr%C3%A3o&amp;author=C.%20Cullinane&amp;author=J.%20Raleigh&amp;volume=70&amp;issue=8&amp;publication_year=2010&amp;pages=2499&amp;doi=10.1158/1538-7445.Am10-2499&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0048">
<span class="label">48.</span><cite>
Li Q., Qian W., Zhang Y., Hu L., Chen S., and Xia Y., “A New Wave of Innovations Within the DNA Damage Response,” Signal Transduction and Targeted Therapy
8, no. 1 (2023): 338, 10.1038/s41392-023-01548-8.
</cite> [<a href="https://doi.org/10.1038/s41392-023-01548-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10485079/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37679326/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Signal%20Transduction%20and%20Targeted%20Therapy&amp;title=A%20New%20Wave%20of%20Innovations%20Within%20the%20DNA%20Damage%20Response&amp;author=Q.%20Li&amp;author=W.%20Qian&amp;author=Y.%20Zhang&amp;author=L.%20Hu&amp;author=S.%20Chen&amp;volume=8&amp;issue=1&amp;publication_year=2023&amp;pages=338&amp;pmid=37679326&amp;doi=10.1038/s41392-023-01548-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0049">
<span class="label">49.</span><cite>
Srivas R., Shen J. P., Yang C. C., et al. “A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy,” Molecular Cell
63, no. 3 (2016): 514–525, 10.1016/j.molcel.2016.06.022.
</cite> [<a href="https://doi.org/10.1016/j.molcel.2016.06.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5209245/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27453043/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cell&amp;title=A%20Network%20of%20Conserved%20Synthetic%20Lethal%20Interactions%20for%20Exploration%20of%20Precision%20Cancer%20Therapy&amp;author=R.%20Srivas&amp;author=J.%20P.%20Shen&amp;author=C.%20C.%20Yang&amp;volume=63&amp;issue=3&amp;publication_year=2016&amp;pages=514-525&amp;pmid=27453043&amp;doi=10.1016/j.molcel.2016.06.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0050">
<span class="label">50.</span><cite>
Bret C., Klein B., and Moreaux J., “Nucleotide Excision DNA Repair Pathway as a Therapeutic Target in Patients With High‐Risk Diffuse Large B Cell Lymphoma,” Cell Cycle
12 (2013): 1811–1812, 10.4161/cc.25115.
</cite> [<a href="https://doi.org/10.4161/cc.25115" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3735686/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23708513/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Cycle&amp;title=Nucleotide%20Excision%20DNA%20Repair%20Pathway%20as%20a%20Therapeutic%20Target%20in%20Patients%20With%20High%E2%80%90Risk%20Diffuse%20Large%20B%20Cell%20Lymphoma&amp;author=C.%20Bret&amp;author=B.%20Klein&amp;author=J.%20Moreaux&amp;volume=12&amp;publication_year=2013&amp;pages=1811-1812&amp;pmid=23708513&amp;doi=10.4161/cc.25115&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0051">
<span class="label">51.</span><cite>
Parvin S., Ramirez‐Labrada A., Aumann S., et al. “LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.” Cancer Cell
36(3): 237‐249
e236 (2019), 10.1016/j.ccell.2019.07.007.
</cite> [<a href="https://doi.org/10.1016/j.ccell.2019.07.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6752209/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31447348/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=LMO2%20Confers%20Synthetic%20Lethality%20to%20PARP%20Inhibition%20in%20DLBCL&amp;author=S.%20Parvin&amp;author=A.%20Ramirez%E2%80%90Labrada&amp;author=S.%20Aumann&amp;volume=36&amp;issue=3&amp;publication_year=2019&amp;pages=237-249&amp;pmid=31447348&amp;doi=10.1016/j.ccell.2019.07.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0052">
<span class="label">52.</span><cite>
Mansoor A., Kamran H., Rizwan H., et al. “Expression of “DNA Damage Response” Pathway Genes in Diffuse Large B‐Cell Lymphoma: The Potential for Exploiting Synthetic Lethality,” Hematological Oncology
42, no. 1 (2024): e3225, 10.1002/hon.3225.
</cite> [<a href="https://doi.org/10.1002/hon.3225" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37795760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematological%20Oncology&amp;title=Expression%20of%20%E2%80%9CDNA%20Damage%20Response%E2%80%9D%20Pathway%20Genes%20in%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma:%20The%20Potential%20for%20Exploiting%20Synthetic%20Lethality&amp;author=A.%20Mansoor&amp;author=H.%20Kamran&amp;author=H.%20Rizwan&amp;volume=42&amp;issue=1&amp;publication_year=2024&amp;pages=e3225&amp;pmid=37795760&amp;doi=10.1002/hon.3225&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0053">
<span class="label">53.</span><cite>
Ferrao P. T., Bukczynska E. P., Johnstone R. W., and McArthur G. A., “Efficacy of CHK Inhibitors as Single Agents in MYC‐driven Lymphoma Cells,” Oncogene
31, no. 13 (2012): 1661–1672, 10.1038/onc.2011.358.
</cite> [<a href="https://doi.org/10.1038/onc.2011.358" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21841818/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Efficacy%20of%20CHK%20Inhibitors%20as%20Single%20Agents%20in%20MYC%E2%80%90driven%20Lymphoma%20Cells&amp;author=P.%20T.%20Ferrao&amp;author=E.%20P.%20Bukczynska&amp;author=R.%20W.%20Johnstone&amp;author=G.%20A.%20McArthur&amp;volume=31&amp;issue=13&amp;publication_year=2012&amp;pages=1661-1672&amp;pmid=21841818&amp;doi=10.1038/onc.2011.358&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0054">
<span class="label">54.</span><cite>
Reddy A., Zhang J., Davis N. S., et al. “Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.” Cell
171(2): 481‐494
e415 (2017), 10.1016/j.cell.2017.09.027.
</cite> [<a href="https://doi.org/10.1016/j.cell.2017.09.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5659841/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28985567/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Genetic%20and%20Functional%20Drivers%20of%20Diffuse%20Large%20B%20Cell%20Lymphoma&amp;author=A.%20Reddy&amp;author=J.%20Zhang&amp;author=N.%20S.%20Davis&amp;volume=171&amp;issue=2&amp;publication_year=2017&amp;pages=481-494&amp;pmid=28985567&amp;doi=10.1016/j.cell.2017.09.027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0055">
<span class="label">55.</span><cite>
Silva S. B., Wanderley C. W. S., and Colli L. M., “Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy,” Frontiers in Immunology
13 (2022): 826577, 10.3389/fimmu.2022.826577.
</cite> [<a href="https://doi.org/10.3389/fimmu.2022.826577" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8860897/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35211121/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Immunology&amp;title=Immune%20Checkpoint%20Inhibitors%20in%20Tumors%20Harboring%20Homologous%20Recombination%20Deficiency:%20Challenges%20in%20Attaining%20Efficacy&amp;author=S.%20B.%20Silva&amp;author=C.%20W.%20S.%20Wanderley&amp;author=L.%20M.%20Colli&amp;volume=13&amp;publication_year=2022&amp;pages=826577&amp;pmid=35211121&amp;doi=10.3389/fimmu.2022.826577&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0056">
<span class="label">56.</span><cite>
Stewart R. A., Pilie P. G., and Yap T. A., “Development of PARP and Immune‐Checkpoint Inhibitor Combinations,” Cancer Research
78, no. 24 (2018): 6717–6725, 10.1158/0008-5472.CAN-18-2652.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-18-2652" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30498083/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Research&amp;title=Development%20of%20PARP%20and%20Immune%E2%80%90Checkpoint%20Inhibitor%20Combinations&amp;author=R.%20A.%20Stewart&amp;author=P.%20G.%20Pilie&amp;author=T.%20A.%20Yap&amp;volume=78&amp;issue=24&amp;publication_year=2018&amp;pages=6717-6725&amp;pmid=30498083&amp;doi=10.1158/0008-5472.CAN-18-2652&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0057">
<span class="label">57.</span><cite>
King M. C., Marks J. H., and Mandell J. B., and G. New York Breast Cancer Study
. “Breast and Ovarian Cancer Risks due to Inherited Mutations in <em>BRCA1</em> and <em>BRCA2</em>
,” Science
302, no. 5645 (2003): 643–646, 10.1126/science.1088759.
</cite> [<a href="https://doi.org/10.1126/science.1088759" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14576434/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Breast%20and%20Ovarian%20Cancer%20Risks%20due%20to%20Inherited%20Mutations%20in%20BRCA1%20and%20BRCA2&amp;author=M.%20C.%20King&amp;author=J.%20H.%20Marks&amp;author=J.%20B.%20Mandell&amp;volume=302&amp;issue=5645&amp;publication_year=2003&amp;pages=643-646&amp;pmid=14576434&amp;doi=10.1126/science.1088759&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0058">
<span class="label">58.</span><cite>
Farmer H., McCabe N., Lord C. J., et al. “Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy,” Nature
434, no. 7035 (2005): 917–921, 10.1038/nature03445.
</cite> [<a href="https://doi.org/10.1038/nature03445" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15829967/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Targeting%20the%20DNA%20Repair%20Defect%20in%20BRCA%20Mutant%20Cells%20as%20a%20Therapeutic%20Strategy&amp;author=H.%20Farmer&amp;author=N.%20McCabe&amp;author=C.%20J.%20Lord&amp;volume=434&amp;issue=7035&amp;publication_year=2005&amp;pages=917-921&amp;pmid=15829967&amp;doi=10.1038/nature03445&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0059">
<span class="label">59.</span><cite>
Wang D., Zhang Y., Wang X., Zhang L., and Xu S., “Construction and Validation of an Aging‐Related Gene Signature Predicting the Prognosis of Pancreatic Cancer,” Frontiers in Genetics
14 (2023): 1022265, 10.3389/fgene.2023.1022265.
</cite> [<a href="https://doi.org/10.3389/fgene.2023.1022265" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9889561/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36741321/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Genetics&amp;title=Construction%20and%20Validation%20of%20an%20Aging%E2%80%90Related%20Gene%20Signature%20Predicting%20the%20Prognosis%20of%20Pancreatic%20Cancer&amp;author=D.%20Wang&amp;author=Y.%20Zhang&amp;author=X.%20Wang&amp;author=L.%20Zhang&amp;author=S.%20Xu&amp;volume=14&amp;publication_year=2023&amp;pages=1022265&amp;pmid=36741321&amp;doi=10.3389/fgene.2023.1022265&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0060">
<span class="label">60.</span><cite>
Chang W. H., Forde D., and Lai A. G. “Dual Prognostic Role of 2‐Oxoglutarate‐Dependent Oxygenases in Ten Cancer Types: Implications for Cell Cycle Regulation and Cell Adhesion Maintenance.” Cancer Communications
39 (2019): 23, 10.1186/s40880-019-0369-5.
</cite> [<a href="https://doi.org/10.1186/s40880-019-0369-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6489267/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31036064/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Communications&amp;title=Dual%20Prognostic%20Role%20of%202%E2%80%90Oxoglutarate%E2%80%90Dependent%20Oxygenases%20in%20Ten%20Cancer%20Types:%20Implications%20for%20Cell%20Cycle%20Regulation%20and%20Cell%20Adhesion%20Maintenance&amp;author=W.%20H.%20Chang&amp;author=D.%20Forde&amp;author=A.%20G.%20Lai&amp;volume=39&amp;publication_year=2019&amp;pages=23&amp;pmid=31036064&amp;doi=10.1186/s40880-019-0369-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0061">
<span class="label">61.</span><cite>
Li L., Zou B. J., Zhao J. Z., et al. “A Novel DNA Damage Repair‐Related Signature for Predicting Prognositc and Treatment Response in Non‐Small Lung Cancer,” Frontiers in Oncology
12 (2022): 961274, 10.3389/fonc.2022.961274.
</cite> [<a href="https://doi.org/10.3389/fonc.2022.961274" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9673481/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36408135/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Oncology&amp;title=A%20Novel%20DNA%20Damage%20Repair%E2%80%90Related%20Signature%20for%20Predicting%20Prognositc%20and%20Treatment%20Response%20in%20Non%E2%80%90Small%20Lung%20Cancer&amp;author=L.%20Li&amp;author=B.%20J.%20Zou&amp;author=J.%20Z.%20Zhao&amp;volume=12&amp;publication_year=2022&amp;pages=961274&amp;pmid=36408135&amp;doi=10.3389/fonc.2022.961274&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0062">
<span class="label">62.</span><cite>
Knittel G., Rehkamper T., Korovkina D., et al. “Two Mouse Models Reveal an Actionable PARP1 Dependence in Aggressive Chronic Lymphocytic Leukemia,” Nature Communications
8, no. 1 (2017): 153, 10.1038/s41467-017-00210-6.</cite> [<a href="https://doi.org/10.1038/s41467-017-00210-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5532225/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28751718/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Two%20Mouse%20Models%20Reveal%20an%20Actionable%20PARP1%20Dependence%20in%20Aggressive%20Chronic%20Lymphocytic%20Leukemia&amp;author=G.%20Knittel&amp;author=T.%20Rehkamper&amp;author=D.%20Korovkina&amp;volume=8&amp;issue=1&amp;publication_year=2017&amp;pages=153&amp;pmid=28751718&amp;doi=10.1038/s41467-017-00210-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0063">
<span class="label">63.</span><cite>
Linders A. N., Dias I. B., Lopez Fernandez T., Tocchetti C. G., Bomer N., and Van der Meer P., “A Review of the Pathophysiological Mechanisms of Doxorubicin‐Induced Cardiotoxicity and Aging,” NPJ Aging
10, no. 1 (2024): 9, 10.1038/s41514-024-00135-7.
</cite> [<a href="https://doi.org/10.1038/s41514-024-00135-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10806194/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38263284/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=NPJ%20Aging&amp;title=A%20Review%20of%20the%20Pathophysiological%20Mechanisms%20of%20Doxorubicin%E2%80%90Induced%20Cardiotoxicity%20and%20Aging&amp;author=A.%20N.%20Linders&amp;author=I.%20B.%20Dias&amp;author=T.%20Lopez%20Fernandez&amp;author=C.%20G.%20Tocchetti&amp;author=N.%20Bomer&amp;volume=10&amp;issue=1&amp;publication_year=2024&amp;pages=9&amp;pmid=38263284&amp;doi=10.1038/s41514-024-00135-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70131-bib-0064">
<span class="label">64.</span><cite>
Deppas J. J., Kiesel B. F., Guo J., et al. “Comparative in Vivo Toxicology of ATR Inhibitors Ceralasertib, Elimusertib, and Berzosertib Alone and in Combination With Ionizing Radiation,” Toxicology and Applied Pharmacology
500 (2025): 117375, 10.1016/j.taap.2025.117375.
</cite> [<a href="https://doi.org/10.1016/j.taap.2025.117375" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12126275/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40339611/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Toxicology%20and%20Applied%20Pharmacology&amp;title=Comparative%20in%20Vivo%20Toxicology%20of%20ATR%20Inhibitors%20Ceralasertib,%20Elimusertib,%20and%20Berzosertib%20Alone%20and%20in%20Combination%20With%20Ionizing%20Radiation&amp;author=J.%20J.%20Deppas&amp;author=B.%20F.%20Kiesel&amp;author=J.%20Guo&amp;volume=500&amp;publication_year=2025&amp;pages=117375&amp;pmid=40339611&amp;doi=10.1016/j.taap.2025.117375&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><p>
Supporting Information S1
</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s001.pdf</a><sup> (149.7KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="caption p"><p>
Supporting Information S2
</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s005.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s005.pdf</a><sup> (18.8KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="caption p"><p>
<strong>Figure S1:</strong> DDR genes are essential genes in DLBCL cells.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s010.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s010.pdf</a><sup> (108.9KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material4_reqid_"><div class="caption p"><p>
<strong>Figure S2:</strong> DNA repair scores are associated with drug response in DLBCL cell lines.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s004.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s004.pdf</a><sup> (90.1KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material5_reqid_"><div class="caption p"><p>
<strong>Figure S3:</strong> Effect of genotoxic drugs on apoptosis, cell cycle and DNA damage induction.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s002.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s002.pdf</a><sup> (112.8KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material6_reqid_"><div class="caption p"><p>
<strong>Figure S4:</strong> Effect of genotoxic drugs on apoptosis, cell cycle and DNA damage protein expression.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s003.jpg" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s003.jpg</a><sup> (718.3KB, jpg) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material7_reqid_"><div class="caption p"><p>
<strong>Figure S5:</strong> Effect of drugs combination on apoptosis, cell cycle and DNA damage proteins expression.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s006.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s006.pdf</a><sup> (705.1KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material8_reqid_"><div class="caption p"><p>
<strong>Figure S6:</strong> Combinations of 4‐OH‐Cyclophosphamide with Chk1i and induces DNA replication stress.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s007.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s007.pdf</a><sup> (116.6KB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material9_reqid_"><div class="caption p"><p>
<strong>Figure S7:</strong> Combination of DDR inhibitors with etoposide in DLBCL cells.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s009.jpg" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s009.jpg</a><sup> (761.1KB, jpg) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material10_reqid_"><div class="caption p"><p>
<strong>Figure S8:</strong> Mononuclear cells from six patients with DLBCL were cultured for 4 days in the presence of CD40L.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12374179/bin/HON-43-e70131-s008.pdf" data-ga-action="click_feat_suppl" class="usa-link">HON-43-e70131-s008.pdf</a><sup> (61KB, pdf) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Hematological Oncology are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/hon.70131"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/HON-43-e70131.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.9 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12374179/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12374179/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374179%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374179/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12374179/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12374179/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40847617/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12374179/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40847617/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12374179/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12374179/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="K6z2tGGPJxnvlgYVFv51tPEdu4VQe6ssMF1Ot6eZHJLFp3HNOufN5QX5NzldSBkI">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
